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ABSTRACT
THE APPLICATION OF HYDROGEN/DEUTERIUM EXCHANGE AND COVALENT LABELING
COUPLED WITH MASS SPECTROMETRY TO EXAMINE PROTEIN STRUCTURE
FEBRUARY 2016
NICHOLAS B. BOROTTO, B.S., NORTHEASTERN UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Richard W. Vachet

Thorough insight into a protein’s structure is necessary to understand how it
functions and what goes wrong when it malfunctions. The structure of proteins,
however, is not easily analyzed. The analysis must take place under a narrow range of
conditions or risk perturbing the very structure being probed. Furthermore, the wide
diversity in size and chemistry possible in proteins significantly complicates this analysis.
Despite this numerous methods have been developed in order to analyze protein
structure. In this work, we demonstrate that mass spectrometry (MS)-based techniques
are capable of characterizing the structure of particularly challenging proteins. This is
done through the study of two model systems: (1) the amyloid forming protein β2microglobulin and (2) the protein therapeutics human growth hormone and
immunoglobulin G1.
β-2-microglobulin (β2m) is an amyloidogenic protein and is the major
constituent of fibrils in the disease dialysis related amyloidosis (DRA). Stoichiometric
concentrations of Cu(II) have been used in vitro to induce the amyloid formation of
β2m, but the structural changes caused by Cu(II) have not been fully elucidated. Other
vi

transition metals, such as Zn(II) and Ni(II), do not cause β2m amyloid formation, yet a
comparison of the structural changes caused by these metals and those caused by Cu(II)
could reveal essential structural changes necessary for amyloid formation. To probe
these different structural changes, we have used a combination of hydrogen-deuterium
exchange (HDX) and covalent labeling together with MS. Results from these
measurements reveal that Cu(II) alone is capable of inducing the cis-trans isomerization
of the X-Pro bond of Pro32 and the other necessary conformational changes that allow
β2m to form an amyloid competent state, even though Ni(II) binds the protein at the
same site. We also find that Zn(II) binding leads to increased dynamics, indicating
increase structural instability, which is consistent with the amorphous aggregation
observed in the presence of this metal.
The second part of this dissertation investigates the use of diethylpyrocarbonate
(DEPC)–based covalent labeling to detect three-dimensional structural changes in
immunoglobulin G1 and human growth hormone after they have been exposed to
degrading conditions. We demonstrate that DEPC labeling can identify both specific
protein regions that mediate aggregation and those regions that undergo more subtle
structural changes upon mishandling of these proteins. Importantly, DEPC labeling is
able to provide information for up to 30% of the surface residues in a given protein,
thereby providing excellent structural resolution. Given the simplicity of the DEPC
labeling chemistry and the relatively straightforward mass spectral analysis of DEPClabeled proteins, we expect this method should be amenable to a wide range of protein
therapeutics and their different formulations.
vii

In the final section of this dissertation, we demonstrate that, in certain instances,
scrambling of the DEPC label from one residue to another can occur during collisioninduced dissociation (CID) of labeled peptide ions, resulting in ambiguity in label site
identity. From a preliminary study of over 30 labeled peptides, we find that scrambling
occurs in about 25% of the peptides and most commonly occurs when histidine residues
are labeled. Moreover, this scrambling appears to occur more readily under non-mobile
proton conditions, meaning that low-charge state peptide ions are more prone to this
reaction. For all peptides, we find that scrambling does not occur during electron
transfer dissociation, which suggests that this dissociation technique is a safe alternative
to CID for correct label site identification.
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CHAPTER 1
MASS SPECTROMETRY AND ITS APPLICATION TO PROTEIN STRUCTURE

1.1 Protein Structure

In order to survive and reproduce, cells must balance their osmotic pressure,
maintain their structure, perform chemistry, and do an assortment of other functions.
Proteins are the means by which cells perform most of these functions. Despite this
wide range of functionality, proteins are simply polymers composed of 20 unique amino
acids. This breadth of function is achieved by varying the identity, order, and orientation
of these amino acids. Thus, in order to understand how cells function and what goes
wrong when they malfunction, a thorough understanding of protein structure and
function is necessary.
Amino acids are small organic molecules that contain an amine, a carboxylic acid,
and often a side chain. The chemistry of these side chains varies widely, ranging from
aliphatic to charged. The order and identity of these amino acids, often referred to as
primary structure, is coded within the DNA of cells. For a protein to achieve its desired
function, side chains that are often distal in primary structure must come closer in
space. To ensure functional proteins, the folding of these polymers must occur with high
fidelity.
To achieve this reproducibility, the folding of a protein is programmed into its
sequence.1 This is accomplished through the pattern in which the hydrophobic and

1

hydrophilic residues are intermixed in the primary sequence. The seclusion of these
hydrophobic residues from water is the major driving force behind protein folding.1,2
This process is referred to as hydrophobic collapse. Once solvent is excluded the protein
must arrange in a way to satisfy the hydrogen bonding of its peptide backbone. In tightly
packed regions, steric constraints limit the backbone to two main geometries capable of
satisfying these bonds. These orientations result in either the formation of a helix or a
strand, which are termed α-helices and β-strands. These structural elements are parts of
a protein’s secondary structure. Proteins are made up of multiple secondary structure
components. How these components orient together to form the final threedimensional configuration is the tertiary structure of a protein. Often understanding the
primary, secondary, and tertiary structure of a protein offers insight in to its function.
Sometimes, however, multiple subunits may be necessary to achieve some functions;
the arrangement of these subunits is referred to as quaternary structure.
In order to fully understand how a protein achieves its function, a complete
understanding of all of these aspects of structure is important. Significant research has
already been dedicated to understanding the primary3–6 and secondary7,8 structure of
proteins. While there has also been significant work dedicated to understanding the
tertiary structure of proteins,9,10 the following work will propose additional
methodology to probe their tertiary and quaternary structure by examining two model
systems: (1) β-2-microglobulin (β2m), and (2) a pair of therapeutic proteins (i.e. IgG1
and HGH).

2

1.1.1 β-2-microglobulin and Dialysis related amyloidosis

The amphiphilic character that leads to the folding of proteins can also lead to
their aggregation. Aggregation is not uncommon. In fact, cells have developed a number
of pathways to recover, degrade, or sequester these aggregates.11 There are some
aggregates, however, which avoid or overwhelm such rescue pathways. Amyloidosis
describes a class of diseases where proteins aggregate into insoluble fibrils. These
fibrous structures are resistant to these degradation pathways and their presence can
be deleterious to the cell or other biological tissues. There are approximately 20 human
diseases that involve this type of aggregation. The specific disease is denoted by the
identity of the aggregating protein and the location of the fibril deposits.12
Many of these amyloidogenic proteins are natively soluble and monomeric.
Despite this, the monomer is somehow stimulated into a normally unpopulated
amyloidogenic conformer that can ultimately form amyloid fibrils.13 Significant work has
been dedicated to understanding and identifying the mechanisms by which these
amyloidogenic conformers are populated for different proteins.12,14–17 One event that
has been shown to initiate aggregation for several of these amyloid-forming proteins is
the binding of transition metals.18–20 This interaction is thought to stabilize an
amyloidogenic competent state mediating the formation of amyloids.19–27 β-2microglobulin (β2m) is one such amyloidogenic protein (Figure 1-1) that can form
amyloid fibrils in the presence of Cu(II).

3

Figure 1-1 Cartoon representation of β-2-mictoglobulin and a schematic illustrating the nomenclature of its β
strands (PDB: 2XKS). The yellow line represents the disulfide between Cys25 and Cys80 on the B and F strands,
respectively.

β2m is normally found as a structural component of the MHC type 1 complex. Its
structure has been characterized in both its native complex and its monomeric state.28,29
β2m is a 99 residue β-sandwich protein that has an approximate molecular weight of
12,000 Daltons. It has been found to be the major constituent of fibrils in the disease
dialysis related amyloidosis (DRA).30,31 Elimination through the kidneys is the major
pathway by which the body disposes of β2m. Patients in renal failure rely on dialysis to
perform the function of the kidney. Dialysis, however, cannot remove β2m effectively.
As a result, its concentration rises from ~0.1 µM to up to ~6 µM in the body.32,33 In this
disease the deposition of these fibrils in joints lead to acute arthropathy,32,34 eventually
necessitating joint replacement.
An abundance of research has been dedicated to understanding the process by
which these fibrils are generated. Despite this, the mechanism by which they are
generated in vivo is not known but it is known that the increased concentration of β2m
4

alone is not sufficient.35,36 Prior research has also shown that acidic conditions,37,38
certain mutations,39,40 cleavage of the six N-terminal amino acids (ΔN6),17,41 limited
proteolysis42, stoichiometric concentrations of Cu(II)22,43–47, and others48,49 have the
capability to induce the amyloidosis of β2m in vitro.37,50 The Cu(II) mediated pathway is
particularly compelling due to the incidence of DRA decreasing significantly after the
institution of Cu(II)-free dialysis membranes.51,52
Thus, the process by which Cu(II) binding induces fibril formation has been the
subject of much study. β2m fibril formation is preceded by the formation of di-, tetra-,
and hexameric species upon Cu(II) binding (Figure 1-2).53 These oligomers, particularly
the dimer54,55 and tetramer,55,56 were characterized and shown to maintain a native-like
structure.53,55,57,58 The effect of Cu(II) on amyloid formation was also shown to be
catalytic as it is released upon a structural rearrangement of the tetramer, and the final
fibrils were shown to be devoid of Cu.57,58 The influence of Cu(II) binding on monomeric
β2m has also been extensively studied, and studies indicate that Cu(II) binding induces
the formation of an amyloidogenic conformer.43,59,60

5

.
Figure 1-2 Mechanism by which β2m is converted by Cu(II) in an amyloidogenic conformer.

Suspected amyloidogenic conformers of β2m have also been studied for several
mutants, including ΔN6,61 P32G,62 and P32A,63 with atomic-level information being
obtained by NMR or X-ray crystallography. The amyloidogenic conformer formed upon
Cu(II) binding has not been completely characterized,44 although, some of the structural
changes necessary to induce the oligomerization of β2m have been revealed.22,46,64,65
The isomerization of the His31-Pro32 amide bond, the movement of Asp59, Arg3,
Phe30, and Trp60 are some of the changes that Cu(II) binding has been shown to
induce.55,64,65 A more thorough understanding of the structural changes caused by Cu
that allow β2m to be transformed into amyloid aggregates may be informative for both
non-Cu(II) induced transformations of β2m and the Cu(II) mediated conversions of other
amyloidogenic proteins.
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1.1.2 Therapeutic Proteins

Amyloid aggregation of proteins is not the only biomedically important type of
protein aggregation. The unfolding and aggregation of protein therapeutics is also a
growing area of interest in need of new tools for probing protein higher order structure.
Protein therapeutics attempt to recover native function through the introduction of
externally produced protein. Human growth hormone (HGH) and insulin were two of the
earliest adopted protein therapeutics, which were used to treat hypopituitarism and
diabetes mellitus type 1, respectively.66–70 Since then, protein therapeutics have become
the fastest growing segment of the pharmaceutical market with approximately 200
proteins approved for use as of 2012.71
Immunoglobulins, which are also known as antibodies, are a class of protein
therapeutics that has been extensively utilized. These proteins are naturally found as
part of the immune system where they are used to recognize and bind foreign antigens.
Immunoglobulin G (IgG) is an example of one of these antibodies. It is made up of two
heavy and two light chains. Each light chain is bound to a heavy by disulfide bonds and
the two heavy chains are also bound together by disulfides, forming a symmetrical 150
kD protein with each half of the structure having six domains. The CH1, CH2, CH3, and CL
domains make up the signaling and structural part of the protein, and have primary
sequences that are fairly constant across IgG molecules. Antigenic specificity is derived
from the variable domains, VH and VL (Figure 1-3). As therapeutics, one use for IgGs is to
stimulate the immune system into targeting malfunctioning cells that normally evade
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recognition such as in cancer or autoimmunity.72,73 The specificity of binding relies on
the proper tertiary structure of the VH and VL domains.74

Figure 1-3 Structure of IgG1 with the domains of the heavy chain (grey) and the light chain (blue) denoted.

Perturbations in the structure of therapeutic proteins can also induce
endogenously occurring antibodies to identify them as foreign. This immunogenicity can
result in a reduction of the potency and efficacy of a drug and potentially lead to its
complete neutralization.75 The immunogenic response is significantly more pronounced
when aggregated protein is introduced into the subject.75 For these reasons, ensuring
the proper tertiary and quaternary structure of a therapeutic protein is of the utmost
importance. A thorough understanding of how protein therapeutics aggregate could
allow for the targeted engineering of these molecules, leading to their improved
stability.76–78
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1.2 Tools for the Analysis of Tertiary and Quaternary Structure

The tertiary and quaternary structure of proteins is not always easily analyzed.
The analysis must take place under a narrow range of conditions or risk perturbing the
very structure being probed. Furthermore, the wide diversity in size and chemistry
possible in proteins significantly complicates this analysis. Despite these challenges,
numerous methods have been developed to analyze the structure of proteins.
Therapeutic and amyloidogenic proteins specifically have been studied using Fourier
transform infrared (FTIR) spectroscopy,79–81 circular dichroism (CD)
spectroscopy,43,79,82,83 size exclusion chromatography (SEC),22,53,57,79,84 dynamic light
scattering (DLS),57,79,85–88 fluorescence spectroscopy,79,88–90 nuclear magnetic resonance
(NMR),87,91–96 X-ray crystallography,97–102 and a host of other techniques. Each method,
however, has its advantages and limitations.
CD and FTIR spectroscopy have been used extensively to probe the secondary
structure of therapeutic and amyloidogenic proteins,7,8,43,79–83,103–105 but they are limited
in their ability to probe tertiary structure.106,107 For example, CD is insensitive to the
changes that Cu(II) binding induces in β2m.43 Another disadvantage for these techniques
is that they average all proteins and protein conformations present in solution.
SEC and DLS both measure the hydrodynamic radius of a protein, which can then
be used to approximate its size. The ability to measure size is particularly useful when
monitoring the soluble aggregation of proteins, making it particularly suited for the
study of amyloidogenic and therapeutic proteins.22,53,57,79,84–88 This ability to measure
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size alone has limited usefulness. With β2m, for example, SEC has shown that the
amyloidogenic conformer possesses a more extended structure, but more detailed
structural information cannot be obtained with this method.39
Fluorescence spectroscopy has been used quite extensively to study protein
structural changes. There are two commonly used versions of this technique that are
applied to proteins: intrinsic fluorescence of tryptophan residues108,109 and extrinsic
fluorescence that relies on an added fluorophore.110 Trp-intrinsic fluorescence has found
use in the analysis of both amyloidogenic111–113 and therapeutic114,115 proteins. Trp
fluorescence alone is unable to completely deduce the tertiary structure of proteins, but
it can be used to monitor the environment of tryptophan residues allowing for some
deductions about tertiary structure.108 Extrinsic fluorescence methods can monitor a
number of attributes depending on the chosen dye. Two commonly used dyes are
thioflavin T (ThT) and 4,4′-bis-1-anilinonaphthalene-8-sulfonate (bis-ANS).110 The
fluorescence of ThT changes when exposed to amyloidogenic aggregates.116,117
Consequently, the use of ThT has become one of the most common methods for
identifying amyloidogenic aggregation.14,15,38,45,88,118 The dye bis-ANS shows a strong
increase in fluorescence when proteins have exposed hydrophobic surfaces110,119 and
has become widely used for measuring the structural integrity of therapeutic
proteins.79,80,114,120,121 While bis-ANS can be used to monitor the proper folding of a
protein, it is unable to identify the exact location where any unfolding occurs. All of the
previously mentioned techniques, while useful, have significant limitations in what can
be deduced about tertiary structure.
10

In contrast, NMR and X-ray crystallography can be used to measure the
secondary, tertiary, and quaternary structure simultaneously, thus often enabling an
atomic level view of protein structure. Both techniques have been extensively used to
study amyloidogenic41,91,93,98,122,123 and therapeutic proteins,96,100–102,124,125 including a
number of IgGs.100,101 β2m has also been analyzed extensively with these techniques,
and the amyloidogenic conformers of the ΔN6 construct and the mutants P32G and
P32A have been characterized using NMR61 and crystallography,62,63 respectively.
While these methods can provide a substantial amount of information, they also
have disadvantages. Firstly, both NMR and X-ray crystallography require significant
analysis time, large quantities of protein, and typically pure proteins. The analysis of
large or heterogeneous proteins also remains challenging for both methods.126–128 Thus,
very few structures of intact IgG proteins have been solved.100 The crystallographic
structure of the P32A mutant displayed an increase in β-strand character along the Dstrand (Figure 1-1).63 This was initially hypothesized to be an important structural
change required to initiate oligomerization. This was later discounted,54 potentially
indicating that this increase in β-strand character may merely be a crystallographic
artifact. These artifacts are created due to the protein being probed in an environment
that it is not found in natively. Another issue with crystallization is that the protein is
crystallized in its lowest energetic state. For amyloidogenic proteins, this is its fibril
form, thus limiting its applicability in amyloidogenic systems. In the case of NMR, the
protein needs to be grown in isotopically-enriched media because only isotopes of
nitrogen and carbon atoms are observable by NMR. NMR also has trouble with
11

paramagnetic metals, and so the data from Cu-binding proteins, for example, has to be
carefully interpreted because of non-specific broadening of resonances. The difficulties
associated with certain protein systems and limitations of both the high resolution and
low resolutions methods necessitates the development of new methodologies.

1.3 Mass Spectrometric Approach to Structure

Mass spectrometry (MS)-based techniques are an alternative that could
potentially fill this need. Unlike NMR and X-ray crystallography, MS is unable to probe
tertiary or quaternary structure directly. Instead, MS relies on reagent molecules that
can react with certain solvent-accessible sites on the protein. These modifications
induce a mass change which can be measured using MS (Figure 1-4). The extent of
modification can be used to measure solvent accessibility or in some cases the dynamics
of the labeled site. These values and, more importantly, changes in these values give
insight into changes in tertiary structure upon some perturbation. Thus, MS-based
methods are best used when comparing a protein under different conditions. While MS
will unlikely ever produce the same insight into structure as X-ray crystallography and
NMR, it is still capable of generating complementary structural information for a wide
range of protein systems.
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Figure 1-4 Generalized work flows for structural mass spectrometry experiments. Bottom-up (fragmentation
prior to ionization) and top-down proteomics (fragmentation after ionization of intact protein) are two means of
reading out the structural information that is obtained by labeling the protein in solution.

Each label site can be used as a diagnostic for changes in nearby tertiary or
quaternary structure. Thus, the structural resolution of MS-based techniques is
dependent on two factors: (1) the number and distribution of probe-able sites on the
protein and (2) the ability to accurately assign which of those sites have been labeled.
While high coverage is desirable, reagents that are capable of modifying multiple sites
often require more complicated analyses. Thus, molecules with a wide range of
specificities have been adopted. Identifying the location of all of these labels relies on
the fragmentation of the protein into smaller pieces. The label location can be assigned
through the identification of which fragments have been modified. The fragment size
and the degree of overlap determine how narrowly the label location can be assigned.
These fragments can either be produced prior to ionization through proteolysis in
bottom-up proteomics or after using tandem mass spectrometry (MS/MS) in a top-
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down proteomics approach. In many cases MS/MS can be applied to proteolysisproduced peptides to more precisely assign label locations.

1.3.1 Hydrogen/Deuterium Exchange (HDX)

In HDX/MS the amide hydrogens of the protein are exchanged with deuterium
(or vice versa). All but one of the 20 common amino acids have an amide bond, enabling
the majority of a protein’s backbone to be probed. When the sample is then analyzed by
a mass spectrometer as in Figure 1-4, a mass shift of one dalton will occur for every
hydrogen atom that has been exchanged (Figure 1-5). The rate at which each amide
hydrogen atom is exchanged is dependent on its accessibility to solvent and whether or
not it is involved in hydrogen bonds. Amides involved in hydrogen bonds are protected
from exchange. Hydrogen bonds, however, often form and re-form as the protein
samples different conformations. Accordingly, more dynamic regions of a protein show
greater amounts of deuterium exchange.129 The ability to measure protein dynamics
opposed to merely solvent accessibility differentiates this method from other MS-based
approaches.

Figure 1-5 Figure illustrates amide hydrogen atoms (small blue circles) being exchanged with deuterium (red
circles). Thus, allowing for regions in the protected core of the protein to be identified.
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This ability to probe dynamics has led to the broad application of HDX in the
analysis of protein structure by MS.130–134 HDX/MS has also been used to probe both
β2m and therapeutic proteins to a limited extent.135–142 Global HDX studies have been
used on β2m to probe the change in dynamics after its dissociation from the MHC-1
complex,135 upon exposure to added reagents such as Cu(II),136 SDS,136 TFE,136 after the
removal of the six N-terminal amino acids,136 and cleaving the protein at Lys58 via
limited proteolysis.137 These studies demonstrated that the dissociation from the MHC-1
complex, binding of Cu(II), truncation, exposure to SDS, and TFE all induce increased
conformational flexibility of β2m. HDX has also found widespread use on many
therapeutic proteins.138,139 Antibodies in particular have been a focus of this research.140
The method has been used for epitope mapping,124,143,144 probing the effects of
chemical degradation,141 and measuring the influence of deglycosylation on the
dynamics of IgG.142
One challenge associated with HDX/MS is the transient nature of the exchanged
amide hydrogens. The lability of the exchangeable hydrogens can lead to scrambling of
the added deuterium during ionization145 or fragmentation in some tandem mass
spectrometric methods.146,147 This scrambling can lead to ambiguous data at best or
completely incorrect results at worst. Another problem is back exchange. Under native
conditions (e.g. pH 7 and 22ºC) exchange is fast enough that any added deuterium can
be lost during the proteolysis, liquid chromatography, and ionization steps of the
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analysis. As a result of these issues, special care and often expensive instrumentation
are required to minimize back exchange and to accurately locate deuterated sites.132

1.3.2 Covalent Labeling Based Methods

Methods that use covalent bond formation to characterize protein structure are
not subject to back exchange. In contrast to HDX, the covalent nature of these
modifications enables the use of MS/MS, often in conjunction with proteolysis, as a
means to improve label assignment. Covalent labels also provide complementary
information to HDX in that they report on protein side chains rather than the protein
backbone.

1.3.2.1 Hydroxyl Radical Footprinting

Hydroxyl radical footprinting (HRF) is a commonly used approach for covalent
labeling.148–152 In this method, hydroxyl radicals are produced through the radiolysis or
photolysis of water or hydrogen peroxide. The produced radicals then oxidize solvent
accessible sites on the protein. These labels are capable of modifying numerous sites on
a protein but tend to label sulfur-containing, aromatic, and aliphatic residues more
rapidly than other residues.150 Just as with HDX, the labeling reagent is roughly the size
of a water molecule allowing for a good approximation of solvent accessibility.
HRF application to amyloidogenic systems is limited, and to our knowledge it has
not been applied to study β2m amyloid formation. HRF has been used to probe the pre-
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amyloid oligomers of Aβ40152,153 and Aβ42.154 The method has also recently been
applied to monitor structural changes in therapeutic proteins.83,114 The technique was
shown to be quite sensitive to subtle structural changes as it was able to distinguish
expired protein therapeutics from fresh ones.83 HRF also demonstrated the ability to
identify the regions of aggregation in therapeutic monoclonal antibodies (mAbs).114
There are some challenges associated with the implementation of HRF. Most
notably, oxidation by hydroxyl radicals can produce over 50 different types of
modifications that can complicate MS analysis.150 Moreover, in its most commonly used
form, a laser or synchrotron source is necessary to generate the radicals, which limits its
widespread applicability.

1.3.2.2 Cross-linking

Other covalent labeling techniques use bifunctional reagents to link residues that
are spatially adjacent despite being distant in primary structure. The cross-linked
peptides are then sequenced and identified by MS, thereby revealing nearby residues
(Figure 1-6). This method has been used to probe the structures of individual proteins155
and protein complexes.156–160 It has also been used to study amyloid forming and
therapeutic proteins, specifically the oligomerization of Aβ161,162 and epitope mapping of
antibodies.163 In many instances the label will only bind at a single site, thereby failing to
produce a cross-link. These so called “dead ends” enable this method to probe solvent
accessibility of these labeled sites, but this feature is not commonly used in protein
structural analyses. One of the major drawbacks with cross-linking is that the size of
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these labels may perturb the structure of the protein. Therefore, any subsequent
labeling could be probing non-native structures. Another challenge associated with
these bifunctional reagents is that they produce two linked peptides of various sizes
each possessing an N- and C-termini. The ability of current proteomics software to
identify these products is hindered by this complexity.157

Figure 1-6 Labeling results in the linking of residues distant in primary structure but spatially adjacent due to
folding. This enables some information about folding to be deduced.

1.3.2.3 Residue Specific Covalent Labeling

Another approach to covalent labeling uses amino acid-specific reagent
molecules to modify solvent exposed residues.164 The extent of modification can be
used to measure solvent accessibility of each site (Figure 1-8). This approach to labeling
is simple as it requires no specialized equipment and typically produces only a single
type of mass addition. A wide range of reagents are available (see Figure 1-7 for
examples), ranging from those that have narrow specificity (e.g. succinimides and
butanedione) to those with broad specificity (e.g. diethylpyrocarbonate (DEPC)).164 DEPC
18

is capable of labeling all nucleophilic residues, enabling the monitoring of approximately
30% of surface residues of the average protein.65,165 The use of DEPC should maintain
the simplicity of this type of covalent labeling while at the same time minimizing the loss
of resolution compared to HDX and HRF.

Figure 1-7 Examples of reagent molecules used for residue-specific covalent labeling.

Residue-specific covalent labeling has been used to study both amyloidogenic
and therapeutic proteins, though their application to therapeutic proteins has been very
limited. To our knowledge, only the carboxylate-specific reagent pair of 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC) and glycine ethyl ester (GEE)
has been used to probe the structure of a monoclonal antibody.166 With amyloidogenic
proteins, this method provides insight into protein-metal and protein-protein
interactions.65,164,165,167 For example, in β2m this method was able to both identify
residues near the Cu(II) binding site and indentify residues near the interface of the
preamyloid dimer.54

19

Figure 1-8 Residue specific labeling modifies solvent exposed sites enabling one to distinguish the core of the
protein from its surface.

Residue-specific covalent labeling is not without drawbacks. The first is that the
sizes of these reagents preclude them from sites that are normally accessible to water.
Consequently, this method does not strictly probe solvent accessibility. Moreover,
labeling with such large labels may perturb the structure of the protein. Thus, any
subsequent labeling could potentially be probing non-native structures. To ensure this is
not happening a number of methods have been developed: (1) limiting the extent of
labeling to approximately one label per protein, (2) monitoring the structure of the
protein through complementary biophysical techniques, and (3) ensuring the secondorder character of the labeling reaction.65,164
All current methodologies that probe the three-dimensional structure of
proteins have limitations. While MS-based approaches are no exception, they provide
complementary structural information, require little sample, and are capable of probing
challenging proteins and protein systems. Despite these potential advantages the
application of these MS-based methods has not been fully explored.

20

The following sections of this dissertation will investigate and discuss the
application of HDX and residue specific covalent labeling to two model systems. The first
system to be discussed in chapter 2 is the amyloid forming protein β-2-microglobulin.
Here we investigate the structural changes induced by copper that make it unique
among metals for inducing amyloid formation. In chapter 3 we will investigate the ability
of residue specific covalent labeling to distinguish changes in therapeutic proteins after
exposure to denaturing conditions. Chapter 4 describes a gas phase phenomenon
where, under particular conditions, certain residue-specific labels can migrate to
different residues within a peptide. The final chapter will discuss the impact of this work
and its future directions.
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CHAPTER 2
CU(II)’S UNIQUE ABILITY TO INDUCE Β-2-MICROGLOBULIN’S AMYLOIDOGENIC
AGGREGATION

2.1 Introduction

Protein amyloids are a special class of protein aggregates that are associated
with several human diseases in which proteins aggregate into insoluble fibrous
structures that are resistant to degradation. There are about 20 human diseases that
involve this type of aggregation and in each case the identity of the protein and the
location of fibril deposition are different. β-2-microglobulin (β2m) is a one such
amyloidogenic protein. It is naturally found as a structural component of the MHC type
1 complex, but in people undergoing dialysis treatment as a result of kidney disease,
β2m forms amyloid fibrils, which are the main pathology of dialysis related amyloidosis
(DRA).30,31 These fibrils congregate in the joints and induce acute arthropathy.32,34
Amyloid formation by β2m is initiated by the inability to eliminate β2m effectively,
resulting in an increase in serum concentration from ~0.1 µM to up to ~6 µM.32,33 An
abundance of research has been dedicated to understanding the process by which these
fibrils are generated. Despite this, the mechanism by which they are generated in vivo is
not known, but it is known that increased concentrations of β2m alone are not
sufficient.35,36 Research has also shown that acidic conditions,37,38 certain mutations,39,40
cleavage of the six N-terminal amino acids,17,41 limited proteolysis,42 stoichiometric
concentrations of Cu(II),22,43–47 and others48,49 can induce the amyloidosis of β2m in
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vitro.37,50 Our group has become interested in the Cu(II) mediated pathway due to the
decreased incidence of DRA upon the use of Cu(II)-free membranes,51,52 and because
Cu(II) is a convenient means of triggering β2m amyloid formation in vitro.
In previous work by our group and others, it has been found that β2m fibrils are
preceded by the formation of soluble di-, tetra-, and hexameric species upon Cu(II)
binding (Figure 1-2).47,53 The oligomers, particularly the dimer54,55 and tetramer55,56
maintain a native-like structure.53,55,57,58 The binding of Cu(II) has been shown to play a
catalytic role in the formation of β2m fibrils as it is necessary for oligomer formation but
is released before the final fibrils are formed.57,58 The influence of Cu(II) binding on
monomeric β2m has also been extensively studied and it has been demonstrated that
Upon binding to the monomeric β2m, Cu(II) induces several structural changes that are
necessary for the formation of the dimer. These structural changes include the cis-trans
isomerization of the His31-Pro32 amide bond that causes a repacking of the
hydrophobic core and the repositioning of Arg3 and Asp59 to enable the formation of
dimer-stabilizing salt bridges.22,55,63
Recent work has also explored how different metals influence β2m aggregation,
including the similar-sized metals Zn(II) and Ni(II).22 Interestingly, Zn(II) binding causes
amorphous aggregation, while Ni(II) binding failed to initiate any aggregation. The latter
observation is particularly intriguing as Ni(II) and Cu(II) both bind to the N-terminus and
His31.22 It has been suggested that metal binding to His31 lowers the barrier for the cistrans isomerization of the His-Pro32,63 so the failure of Ni(II) to cause amyloid formation
is a curious observation. In this work we set out to elucidate the amyloid-causing
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structural changes initiated by Cu(II) binding that evidently do not occur upon Ni(II) and
Zn(II) binding. Our results show that only Cu(II) is able to cause the necessary Pro32
isomerization, but we also find other subtle structural changes that are necessary for
the formation of β2m amyloids. Overall, our results highlight the fact that very specific
conformational changes are necessary to achieve the amyloid-competent state of β2m.

2.2 Experimental Procedures

2.2.1 Materials

Diethylpyrocarbonate (DEPC), dimethyl(2-hydroxy-5-nitrobenzyl)sulfonium
bromide (HNSB), deuterium oxide, pepsin, imidazole, 3-morpholinopropanesulfonic acid
(MOPS), potassium acetate, potassium bromide, urea, zinc sulfate, deuterium oxide, and
dithiothreitol (DTT) were obtained from Sigma-Aldrich (St. Louis, MO). Urea was
purchased from Mallinckrodt Chemicals (Phillipsburg, NJ). Trypsin and chymotrypsin
were purchased from Promega (Madison, WI) and Roche Diagnostics (Indianapolis, IN)
respectively. Tris(hydroxymethyl)-aminomethane (Tris) and
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) were purchased from EM
Science (Gladstone, NJ). Human β2m purified from human urine was purchased from
Lee Biosolutions (St. Louis, MO). Ammonium acetate, methanol, acetonitrile, glacial
acetic acid, copper sulfate, and nickel sulfate were obtained from Fisher Scientific (Fair
Lawn, NJ). Centricon molecular weight cutoff (MWCO) filters were obtained from
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Millipore (Burlington, MA). Deionized water was prepared from a Millipore (Burlington,
MA) Simplicity 185 water purification system.

2.2.2 Sample Preparation

For HDX experiments a stock of 4.1 mM β2m was made in 25 mM MOPS and 150
mM potassium acetate at pH 7.4. All stocks were made fresh daily. For HNSB labeling
experiments a 75 µM solution of β2m was prepared in 150 mM potassium acetate, and
25 mM MOPS (pH 7.4). For DEPC reactions 100 µM β2m in 200 mM potassium acetate,
500 mM urea, and 25 mM MOPS (pH 7.4) at 37 °C. All components were equilibrated at
22 °C prior to metal addition, and immediately returned to 37 °C after mixing. In all
experiments the following metal to β2m ratios were used: Cu 2:1, Ni 16:1, and Zn 4:1.
These ratios were chosen to ensure that the metal was 95% bound based on previous Kd
measurements.44

2.2.3 Hydrogen/Deuterium exchange (HDX)

Concentrated stocks of β2m, potassium acetate and MOPS buffer, and the
desired metal salt were all made and diluted into D2O simultaneously. For all HDX
experiments, the resulting concentrations were 75 µM β2m, 25 mM MOPS 150 mM
potassium acetate and either 300 µM Zn, 1200 µM Ni, or 150 µM Cu. The total volume
of the reaction mixture was 55 µL. The samples were then allowed to incubate in
deuterium for 60, 80, 120, 240, 420, 660, 1200, 2400, 5400, or 10800 sec after which the

25

sample was placed on ice for an additional 30 sec. The exchange reaction was then
stopped by lowering the solution pH to 2.5 using a solution of formic acid that also
contained 100 mM TCEP. The total volume after quench was 110 µL. The sample was
allowed to sit on ice for 1.5 min prior to proteolysis with pepsin.

2.2.4 Covalent Labeling

Two types of covalent labeling reactions were conducted. The first used HNSB to
modify solvent exposed Trp residues.164 Stock solutions of HNSB were prepared in
water. Labeling of β2m by HNSB was performed for 45 sec at 22 °C and was initiated
through the addition of 68.5 µM of HNSB. The total reaction volume was typically 27 µL.
The HNSB labeling reaction was quenched through the addition of 10 mM tryptophan.
The second type of covalent labeling reaction involved the reagent DEPC, which
can label solvent exposed His, Tyr, Thr, Ser, and Lys residues.54,55,65,164 Stock solutions of
DEPC were prepared in acetonitrile. DEPC labeling of β2m was performed for 1 min at
37 °C and was initiated by adding 0.25 mM DEPC. The total reaction volume for the
experiments was 30 µL, and the total amount of acetonitrile added was < 1.5 %. The
reactions were quenched after 1 min by adding 5 mM imidazole.

2.2.5 Proteolytic Digestion

β2m samples that underwent HDX were digested using pepsin. The digestion
was initiated through the addition of ~1.9 µM pepsin to the already quenched samples,
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resulting in a 1:20 pepsin/β2m ratio. The digestion was allowed to proceed on ice for 6
min. The digested samples were then immediately analyzed by LC/MS.
DEPC labeled β2m samples were purified using a 10,000 MWCO filter and
reconstituted with 25 mM Tris-HCl (pH 7) and 1 mM CaCl2 to a final concentration of 300
µM. Purified β2m samples were first reacted with 10 mM DTT at 37 °C for 45 min to
reduce the disulfide bonds. The reduced protein samples were then unfolded in 12%
acetonitrile at 37 °C for 45 min. Trypsin or chymotrypsin (1 µg/µL) was then added to
the modified samples to yield a final enzyme/substrate ratio of 1:20. All samples were
digested at 37 °C for 16 h before inactivating the enzymes by the addition of 2 µL of
acetic acid. The samples were then immediately analyzed by LC/MS.

2.2.7 HPLC Separation

To analyze the digests from both the HDX and covalent labeling experiments, an
HP1100 (Agilent, Wilmington, DE) HPLC system with a C18 column (15 cm x 2.1 mm, 5
µm particle size) from Supelco, (St. Louis, MO) was used. A 5 µL injection loop and an
injection volume of 7 µL were used for all replicates. Peptic fragments of the H/D
exchanged samples were eluted at a flow rate of 0.25 mL/min using a gradient of
acetonitrile containing 0.1% formic acid that increased 1 to 23% during the first minute,
23 to 24% from 2 to 8 minutes, and then from 24 to 99% from 8 to 11 minutes. The
remaining percentage of the mobile phase was water with 0.1% formic acid. The LC
separation for HDX was performed on ice to minimize back exchange. The DEPCmodified proteolytic fragments were separated using a linear gradient of methanol with
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0.1% acetic acid that increased from 5 to 70% over 30 min and 70 to 100% over the final
3 min. The remaining percentage of the mobile phase was water with 0.1% acetic acid.
Some of the HNSB-labeled β2m samples were analyzed as intact proteins. To do
this, the samples were first desalted using a Thermo Scientific Ultimate 3000 HPLC
system (Thermo Scientific, Tewksbury, MA) fitted with a Protein MicroTrap (Michrom,
Auburn, CA). A 5 µL injection loop and an injection volume of 7 µL were used for all
replicates. The protein was eluted using an acetonitrile gradient that increased from 1 to
99% over 5 min at a flow rate of 4 µL/min.

2.2.9 Mass Spectrometry

Mass spectral analyses of the HPLC separated samples from the HNSB labeling
experiments and the HDX reactions were acquired on a Bruker Amazon ETD (Billerica,
MA) quadrupole ion trap mass spectrometer equipped with an electrospray ionization
source. The electrospray source conditions, including the voltage and temperature,
were chosen to optimize the peptide signal. Tandem mass spectra were acquired using
collision-induced dissociation (CID) with isolation widths of 1.0 Da and excitation
voltages between 0.6 and 1.0 V.
The DEPC-labeled β2m samples were analyzed using a Bruker Esquire-LC
quadrupole ion trap mass spectrometer (Billerica, MA) equipped with an ESI source. The
ESI source was operated at a spray voltage of 3.5 kV, and the capillary temperature was
set at 300 °C. The voltages for the transfer optics between the ESI source and the ion
trap were optimized for maximum signal, with typical skimmer 1 and capillary offset
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values of 30-35 V and 50-60 V, respectively. Tandem mass spectra were acquired using
CID with isolation widths of 1.0 Da and excitation voltages between 0.6 and 1.0 V.

2.2.10 Solvent Accessibility Calculations

To calculate the solvent accessibility of surface residues, the online tool
GetArea168 was used on the intact (pdb: 2xks) and truncated (pdb:2xku) structures of
β2m solved that were described by Eichner et al.61

2.3 Results

Amyloid formation by β2m is thought to be initiated by the cis-trans isomerization
of the His31-Pro32 amide bond. Evidence for this conformational switch has come from
studies of β2m in the presence of acid and Cu(II) as well as from results from the ΔN6
mutant.61,63,64 In each instance, the isomerization of the His31-Pro32 amide bond
induces a repacking of the hydrophobic core50,53,60,62,63,112 and changes in the hydrogen
bonding between the B, E, and D β strands. A comparison of the NMR structures of wildtype protein and the ΔN6 mutant reveal these structural changes and provide a model
for the amyloidogenic conformer (Figure 2-1 and Table 2-1). Because Ni(II) and Zn(II) are
unable to stimulate β2m amyloid formation, whereas Cu(II) can, we hypothesize that
Ni(II) and Zn(II) do not enable β2m populate the amyloidogenic state. To test the
hypothesis, we used HDX/MS and covalent labeling/MS to probe the structural changes
caused by metal binding and compared them to changes that are expected for the
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amyloidogenic conformer. Changes in hydrogen bonding (e.g. fraying between the B, E,
and D β strands) can be probed using HDX and repacking of the hydrophobic core, most
notably the burial of Trp60, can be probed using the tryptophan specific label
dimethyl(2-hydroxy-5-nitrobenzyl)sulfonium bromine (HNSB) (Figure 2-2).164,169,170

Figure 2-1 NMR structures of β2m (grey, PDB:2XKS) and ΔN6 (green, PDB:2XKU) The burial Trp60, the
exposure of Phe30, and isomerization of the x-pro bond of Pro32 are illustrated as sticks in both structures. The
numbers on the figure illustrate the distance between the D- and E-(left ) and the E- and B- (right) strands in
angstroms.

Figure 2-2 Scheme of NHSB labeling a tryptophan. Modification leads to a mass change of 151 Daltons.
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Table 2-1 Observable structural changes that occur during the conversion of β2m from its native state to its
amyloidogenic conformer

N-terminus
Pro32
Phe30
Phe62
Phe56
Tyr63
Trp60
B-E strand
D-E Strand
Surface residues
Secondary Structure

Displaced
Isomerization
Exposure
core repacking
core repacking
core repacking
Burial
Fraying
Fraying
Changes in solvent accessibility
Mostly intact

2.3.1 Cu-β2m vs. β2m

Cu has been shown to initiate the amyloid formation of β2m by catalyzing the
cis-trans isomerization of the His31-Pro32 amide bond.63 Evidence for the consequent
structural changes can be found in both HDX and covalent labeling studies. A
comparison of the HDX/MS results (Figure 2-3) from β2m with and without Cu(II) reveal
increased amide exchange around Tyr66 and Tyr67, just as would be expected from the
fraying of the B, E, and D β strands (Figure 2-3 Table 2-1). Increased amide exchange
would also be expected around Cys25 and His51. While this increased exchange is
evident at longer exchange times, the large proteolytic fragments (10-25 and 40-55) that
are obtained also include the A-B loop and C-D loop. Thus, these fragments also have 9
and 11 unprotected amide hydrogens, respectively, causing the change to be less clear
on these rapidly exchanging fragments (Figure 2-4). HDX in the remainder of the
protein’s backbone remains essentially the same with and without Cu(II), which is
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consistent with most of the protein’s backbone retaining its native-like structure upon
converting to the amyloidogenic state (Table 2-1).

Figure 2-3 Extent of HDX at Tyr66 and Try67 without and with Cu(II). These graphs are obtained through the
subtraction of three overlapping fragments 63-65, 63-66, and 63-67. These are indicative of increased dynamics
between both the B- and E- β strands and the D- and E- β strands.

Figure 2-4 Extent of HDX for the peptic fragments 10-25 and 40-55 without and with Cu(II). Because these
fragments contain unstructured regions along with β strands, changes in the extent of exchange are somewhat
obscured by the fast exchanging unstructured regions.

Another key difference between the native protein and its amyloidogenic state is
the burial of Trp60 upon cis-trans isomerization of His31-Pro32 amide bond. To probe
the extent of Trp60 burial upon Cu(II) binding, we used the Trp-specific reagent HNSB,
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which reacts with solvent exposed Trp residues. β2m has two Trp residues (e.g. Trp60
and Trp95), but only Trp60 is solvent exposed. Upon using a 45 sec pulse of HNSB, we
find that labeling at Trp60 remains essentially unchanged for up to 60 min in the
absence of Cu(II) (Figure 2-5). When Cu(II) is present, however, Trp60 undergoes a timedependent decrease in labeling that is consistent with burial of Trp60 over time as the
amyloidogenic state is populated (Figure 2-5). Trp95 also undergoes a slight increase in
labeling efficiency when Cu(II) is present, which is consistent with it becoming more
exposed in the amyloidogenic state. An interesting aspect of the decrease in Trp60
labeling over time is that it seems to indicate the rate at which the amyloidogenic state
is formed after Cu(II) is added. Future work will explore this further.

Figure 2-5 HNSB labeling of intact β2m in the presence and absence of metals. The absence of metal and the
presence of Zn(II) or Ni(II) induce no change in labeling with 60 minutes. The presence of Cu(II), however,
causes a decrease in labeling over time, which is consistent with the burial of Trp60 upon formation of the
amyloidogenic state.

Another characteristic of the amyloidogenic state is the decreased solvent
accessibility of several residues in addition to Trp60 (Table 2.1). A fraction of these

33

residues, which are highlighted in Table 2-2 can be probed by covalent labeling with
DEPC. A comparison of the reactivity of these residues in the presence and absence of
Cu(II) reveals that most of these sites follow the expected trend upon Cu(II) binding
(Table 2-3). For example, Lys19, and Lys75, which are expected to undergo a 25%, and
15% decrease in solvent accessibility, respectively, each show a drop in labeling
efficiency. It should be noted, though, that not all residues undergo the expected
change in reactivity (e.g. Tyr67). This fact might be due to subtle, but important,
differences between the Cu-induced amyloidogenic state and the amyloidogenic
structure adopted by the ΔN6 mutant used as the model system.
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Table 2-2 Atom specific solvent accessibility for intact β2m (2XKS), ΔN6 (2XKU), and the change between the
structures for DEPC probable atoms
Solvent accessibility
Solvent accessibility
(Å2)
(Å2)
#
Atom
Residue
#
Atom
Residue
2XKS 2XKU Change
2XKS 2XKU Change
1
N
ILE 1
32.1
867 OG
SER 55
6.1
20.7
14.6
65
OG1
THR 4
23.7
898 OG
SER 57 17.8
13.9
-3.9
96
NZ
LYS 6
37.8
912 NZ
LYS 58 30.8
37.4
6.7
173 OH
TYR 10 21.0
32.2
11.2
967 OG
SER 61
9.7
10.2
0.6
188 OG
SER 11
4.6
1.5
-3.1
1004 OH
TYR 63 17.3
27.0
9.7
224 ND1
HIS 13 10.9
2.0
-9.0
1063 OH
TYR 66 12.4
13.1
0.7
227 NE2
HIS 13 15.3
13.5
-1.7
1084 OH
TYR 67 26.4
34.3
8.0
303 NZ
LYS 19 34.7
26.2
-8.5
1099 OG1
THR 68
0.9
0.0
-0.9
322 OG
SER 20 21.5
27.1
5.7
1148 OG1
THR 71 17.1
12.4
-4.7
416 OH
TYR 26 29.7
31.6
1.9
1176 OG1
THR 73
1.1
0.8
-0.4
447 OG
SER 28
2.7
21.7
18.9
1208 NZ
LYS 75 40.3
34.5
-5.7
486 ND1
HIS 31
6.2
6.7
0.6
1260 OH
TYR 78
5.6
5.2
-0.3
489 NE2
HIS 31 11.4
10.1
-1.3
1350 ND1
HIS 84
0.0
0.0
0.0
516 OG
SER 33 15.9
17.4
1.5
1353 NE2
HIS 84
2.1
2.4
0.4
642 NZ
LYS 41 29.0
14.2
-14.8
1382 OG1
THR 86
0.0
28.1
28.1
758 NZ
LYS 48 35.7
39.6
3.8
1415 OG
SER 88 20.0
26.9
7.0
809 ND1
HIS 51
3.3
0.6
-2.7
1460 NZ
LYS 91 36.6
29.9
-6.7
812 NE2
HIS 51 17.3
11.8
-5.4
1517 NZ
LYS 94 16.2
35.9
19.7
825 OG
SER 52 19.1
27.6
8.5
Table 2-3 Modification percentages for each modified residue in the absence and presence of Cu(II), Ni(II), or
Zn(II)

Change in
apo-β2m
Cu(II)
Ni(II)
SASA (Å2)
His13
-1.7
47 ± 2
46 ± 3
46 ± 2
Lys19
-8.5
22 ± 1
19 ± 2
18.0 ± 0.7
Ty26
1.9
0.75 ± 0.07 0.79 ± 0.05 1.10 ± 0.05
Ser28α
18.9
0.24 ± 0.01 0.17 ± 0.02 0.35 ± 0.02
His31α
-1.3
1.8 ± 0.1
0.7 ± 0.1
1.6 ± 0.1
α
Ser33
1.5
1.7 ± 0.1
1.1 ± 0.1
1.11 ± 0.06
His51
-5.4
61 ± 3
61 ± 4
72 ± 2
Ser57/Lys58
6.7
43 ± 2
42 ± 3
19.9 ± 0.8
Tyr63β
9.7
7.1 ± 0.5
4.3 ± 0.3
3.6 ± 0.3
Tyr67
8.0
2.1 ± 0.1
1.75 ± 0.06
2.4 ± 0.1
Lys75
-5.7
0.36 ± 0.04 0.33 ± 0.02 0.35 ± 0.04
Ser88
7.0
63 ± 3
65 ± 3
60 ± 1
Lys94
19.7
30 ± 2
29 ± 2
39 ± 3
α
Labeling may be influenced due to proximity to Cu(II) binding site.
β
Labeling may be influenced by the binding of Cu by Asp59.
Residue
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Zn(II)
46
24
0.75
0.26
1.40
1.6
81
46
5.4
2.01
0.52
74
39.7

±
±
±
±
±
±
±
±
±
±
±
±
±

3
2
0.03
0.01
0.05
0.1
4
2
0.3
0.08
0.04
1
0.5

Changes in the HDX and covalent labeling behavior of β2m with and without
Cu(II) at the expected locations provide a benchmark against which the Zn(II) and Ni(II)
bound proteins can be compared. This comparison enables us to determine whether
Zn(II) and Ni(II) induce the amyloidogenic conformer.

2.3.2 Ni-β2m vs. β2m

The influence of Ni(II) binding on β2m is particularly interesting as it binds in a
very similar location to Cu(II), yet it induces no oligomerization or aggregation.22 When
the Ni(II)-bound form of β2m is investigated and compared to the metal free protein
using HDX/MS, we find no increase in exchange at Tyr66, suggesting that the hydrogen
bonding between the B and E strands is unchanged (Figure 2-6). This lack of change is in
stark contrast to the Cu(II) bound form (Figure 2-3). A slight increase in dynamics
between the D and E strands (Figure 2-6, Tyr67 data) is observed, but this increase is
extensive than when Cu(II) is bound to the protein. The complementary proteolytic
fragments (10-25 and 40-55) do not show any significant increase in exchange upon
Ni(II) binding (Figure 2-7). Overall, the HDX results with Ni(II)-bound form of the protein
suggest that Ni(II) binding does not induce the same structural change as Cu(II) binding.

36

Figure 2-6 Extent of HDX at Tyr66 and Try67 without and with Ni(II). These graphs are obtained through the
subtraction of three overlapping fragments 63-65, 63-66, and 63-67. These are indicative of increased dynamics
between both the B- and E- β strands and the D- and E- β strands.

Figure 2-7 Extent of HDX for the peptic fragments 10-25 and 40-55 without and with Ni(II). Because these
fragments contain unstructured regions along with β strands, changes in the extent of exchange are somewhat
obscured by the fast exchanging unstructured regions.

Changes in the solvent accessibility of Trp60 upon binding Ni(II) were also
assessed using HNSB labeling. As indicated in Figure 2-5, the metal-free protein and the
Ni(II)-bound protein undergo no change in HNSB labeling over a period of 60 min.
Covalent labeling with DEPC also suggests different structural changes upon Ni(II)
binding (Table Y). DEPC labeling of the Ni(II)-bound protein shows significant deviations
from the Cu(II)-bound form at Tyr26, Ser28, His51, Lys58, Tyr67, and Lys94. The full
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consequences of these changes are not clear, but these data re-emphasize the intriguing
observation that Cu(II) and Ni(II) induce different structural changes despite both having
the N-terminus and His31 as common binding sites. The fact that Trp60 is not buried
upon Ni(II) binding, together with minimal changes in HDX behavior, strongly suggests
that NI(II) binding does not induce the cis-trans isomerization of Pro32. Evidently Ni(II)
binding to His31 is not sufficient to induce the isomerization that is observed with Cu(II).
Furthermore, the fact that Ni(II) binding does induce a slight increase in amide exchange
between the D and E strands, yet does not induce oligomerization or aggregation,
indicates that the destabilization of the D strand alone is not enough to induce
aggregation.

2.3.3 Zn-β2m vs. β2m

The HDX behavior of the Zn(II)-bound form of β2m is notably different than the
exchange behavior of the Cu(II)-bound form. Changes in amide exchange induced by
Zn(II) binding are evident even at the first measured time point at many different site in
the protein (Figures 2-8, 2-9 and 2-10), possibly signifying a decrease in protein stability.
Increased exchange in the presence of Zn(II) is consistent with the fact that Zn(II)
binding destabilizes β2m by as much as 14 kJ/mol.44 Like the Ni(II)-bound form of β2m,
Zn(II) fails to induce an increase in exchange between the B and E strands, despite the
overall increase in protein dynamics. Unlike Ni(II), however, Zn(II) does increase
exchange at the D and E strands (Figure 2-8) and near the A-B loop (Figure 2-9). Even
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though Zn(II) does cause an increase in the dynamics at the D and E, the increase in
exchange is less than that observed upon Cu(II) binding.

Figure 2-8 Extent of HDX at Tyr66 and Try67 without and with Zn(II). These are indicative of increased
dynamics between both the B- and E- β strands and the D- and E- β strands. These graphs are obtained through
the subtraction of three overlapping fragments 63-65, 63-66, and 63-67.

Figure 2-9 Extent of HDX for the peptic fragments 10-25 and 40-55 without and with Zn(II). Because these
fragments contain unstructured regions along with β strands, changes in the extent of exchange are somewhat
obscured by the fast exchanging unstructured regions.
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Figure 2-10 HDX uptake for each residue at after 2, 40, and 180 min of incubation in deuterium. These are
derived from overlapping peptides produced by proteolysis.

Covalent labeling results with HNSB and DEPC indicate that Zn(II) causes β2m to
adopt a very different structure than the Cu(II)-bound form of the protein. HNSB
labeling of the Zn(II) bound protein and the metal free protein are essentially
equivalent, indicating that Trp60 is not buried upon Zn binding (Figure 2-5). This result
likely suggests that the cis-trans isomerization of the His31-Pro32 amide bond does not
occur upon Zn binding. Moreover, DEPC labeling in the presence of Zn(II) leads to
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significant deviations in labeling as compared to the Cu(II)-bound form, including at
Lys19, His51, Lys58, Tyr67, Lys75, Ser88, and Lys94. Taken together, the HDX and
covalent labeling data suggest that Zn(II)-binding does not result in the formation of the
amyloidogenic conformer.

2.4 Discussion

The amyloid formation by β2m is thought to proceed by the formation of an
amyloidogenic precursor that is formed by the cis-trans isomerization of the His31Pro32 amide bond. This isomerization initiates the re-positioning of a number of
residues including: Asp59, Arg3, Phe30, and Trp60.50,60,53,112,62,63 The binding of Cu(II) to
monomeric β2m has been shown to induce these structural changes and initiate
oligomerization.63,43 The ability of Cu binding to induce oligomerization and its binding
site at a nearby residue (His31) lead to the thought that metal binding near Pro32
lowered the barrier to the cis-trans isomerization.44,46 To further investigate the
influence of transition metals on the structure of β2m, the complexes of Zn(II) and Ni(II)
were investigated.
The binding of these three metals to β2m leads to significantly different
outcomes. While the binding of Zn to β2m leads to aggregation, the aggregates are SDSsoluble amorphous aggregates, suggesting that Zn initiates a significantly different
pathway than Cu. These amorphous aggregates are consistent with the fact that Zn
binds to a very different site on the protein than Cu(II).22 In contrast, Ni(II) binding does
not stimulate any oligomerization or aggregation, as the protein remains monomeric,
41

despite the fact that Ni(II) binds to a similar site as Cu(II).22 These different outcomes
suggest that unlike Cu Zn and Ni do not promote the formation of the amyloidogenic
precursor. To provide structural support for the hypothesis, we applied HDX and CL
together with mass spectrometry. Most of β2m undergoes only minor structural
changes upon the binding either metal. There are, however, regions that are affected
differently by each metal. Zn binding initiates the most significant structural changes,
leading to increased exchange in several locations even at the shortest time points,
suggesting decreased stability. This decrease in stability between the D and E β strands
and the A and B loop likely explains the propensity for the complex to amorphously
aggregate. One region that undergoes increased HDX and that is particularly intriguing is
the region near the B and E β strands. This region also demonstrates an increase in
dynamics upon the binding of Cu. Because Zn also causes increased dynamics in this
region but does not initiate amyloid formation, structural fluctuations at these sites are
clearly not sufficient to induce the formation of the amyloid precursor.
Covalent labeling of Trp60 provided an important indicator of the formation of
the amyloidogenic precursor. Only Cu(II) of the three metals was able to induce the
burial of Trp60; burial of this residue is a key signature of the amyloidogenic
precursor.63,64 DEPC labeling also revealed other residues that undergo changes in
solvent accessibility, and only Cu(II) binding show changes that are consistent with the
amyloidogenic precursor as each metal has different effects on the solvent accessibility
of residues including Lys19, His51, Lys58, Tyr67, Lys75, Ser88, and Lys94. The differences
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in solvent accessibility upon binding each metal further suggest that each metal
promotes the formation of different structures.
The use of both HDX and CL provides complementary information that can be
used to generate a more detailed understanding of the changes in β2m structure upon
metal binding. The use of HNSB, in particular, is interesting because it is an easy method
for monitoring the formation of the amyloidogenic species of β2m. The ability to easily
monitor this species could allow one to probe the rate at which the amyloidogenic
precursor is formed under different conditions.

2.5 Conclusions

In this work we demonstrate that only Cu(II) binding to β2m, and not Ni(II) and
Zn(II) binding, is capable of inducing its transformation into an amyloid competent state.
The results described here highlight the fact that specific structural changes, and not
just any partial unfolding, are essential for achieving the amyloidogenic state of this
protein. This conclusion is most evident from a comparison of the structural changes
caused by Cu(II) and Ni(II). While Ni(II) binds the protein in a similar manner as Cu(II), it
appears to be unable to cause the cis-trans isomerization of the His31-Pro32 amide
bond, which is essential for the formation of the amyloidogenic conformer. Zn(II)
binding increases the overall structural dynamics of β2m, but these increased dynamics
do not result in the formation of the amyloidogenic conformer. Instead, the overall
decrease in stability caused by Zn(II) binding leads to the amorphous aggregation of
β2m observed in the presence of this metal. In addition to obtaining some new insight
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into the specific structural changes that are necessary for β2m amyloid formation, this
work also demonstrates that covalent labeling of Trp60 by HNSB has the potential to
measure the formation rate of the amyloidogenic conformer, which could be a useful
tool for understanding more deeply the factors that influence β2m amyloid formation.
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CHAPTER 3
INVESTIGATING THERAPEUTIC PROTEIN STRUCTURE WITH DIETHYLPYROCARBONATE
LABELING AND MASS SPECTROMETRY

This chapter is adapted from a paper published as: Borotto, N.B., Zhou Y.,Hollingsworth,
S. R., Hale J. E., Graban, E., Vaughan, R. C., Vachet, R. W. (2015) Investigating
Therapeutic Protein Structure with Diethylpyrocarbonate Labeling and Mass
Spectrometry. Anal. Chem. (In press)

3.1 Introduction

Protein therapeutics are the fastest growing segment of the pharmaceutical
market, accounting for one-third of the overall late-stage drug development pipeline.
They are anticipated to represent 20% of the total pharmaceuticals market value by
2017.171 One key element in ensuring the safety and efficacy of these biologic drugs is
the ability to measure and control the three dimensional (3D) structure of the protein
active ingredients. In contrast to more traditional small molecule therapeutics, however,
obtaining accurate, high resolution measurements of protein structures has proven to
be extremely challenging.
Current structural techniques fall into two major categories: (1) rapid, low
resolution techniques and (2) time and sample intensive, high resolution techniques.85
Intrinsic fluorescence, circular dichroism (CD), dynamic light scattering (DLS), differential
scanning calorimetry (DSC), and activity assays are examples of the first type. These
methods provide an ensemble average of structures or are sometimes insensitive to
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certain structural changes. NMR and X-ray crystallography are important examples of
powerful high resolution techniques, but these methods are time-consuming, require a
large amount of protein, and are not amenable to all proteins. Thus, there is a growing
need for other techniques that can provide better resolution than the first category of
techniques but do so in way that is easier and faster than the second category of
techniques.
Mass spectrometry (MS)-based techniques offer an alternative because they can
be rapid, provide moderate resolution, and can be sample efficient. Accordingly, these
techniques have begun to fill an important niche in protein therapeutic analyses. The
primary techniques used for monitoring protein solution structure by MS are
hydrogen/deuterium exchange (HDX), chemical cross-linking, and covalent labeling. In
HDX the mass spectrometer is used to measure the exchange of amide hydrogens for
deuterium (or vice versa), and the extent of exchange at individual sites provides an
indication of solvent accessibility and protein dynamics near that site. HDX/MS has been
widely used to analyze protein structure130,131,172–174 and recently has been applied to
characterize the structure of protein therapeutics.139,140,142,175 One challenge associated
with HDX/MS is the transient nature of the label. As a result, special care and often
expensive instrumentation are required to minimize back exchange and to accurately
locate deuterated sites.
Methods that use covalent bond formation to characterize protein structure are
not subject to back exchange. They also provide complementary information by
reporting on protein side chains. Chemical cross-linking typically uses bifunctional
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reagents to link residues that are spatially adjacent despite being distant in linear
sequence. The cross-linked peptides are then sequenced and identified by MS, thereby
revealing nearby residues. This method has been used to probe the structures of
individual proteins155 and protein complexes.156,158–160 While this technique is not
commonly used to study protein therapeutics, it has been used for antibody epitope
mapping.163 Other covalent labeling techniques use monofunctional reagents to monitor
residue solvent accessibility as a means of probing structure. Hydroxyl radical
footprinting (HRF) is the most common of these techniques.148–151 In this method,
hydroxyl radicals are produced through radiolysis or photolysis of water or hydrogen
peroxide, and the resulting radicals then oxidize solvent accessible sites on the protein.
Because of its broad reactivity and success with other protein systems, HRF has recently
been applied to monitor structural changes in therapeutic proteins.83,114 The technique
was shown to be quite sensitive to subtle structural changes as it was able to distinguish
expired protein therapeutics from fresh ones.83 HRF also demonstrated the ability to
identify the regions of aggregation in therapeutic monoclonal antibodies (mAbs).114
While HRF shows great promise for studying therapeutic proteins, there are some
challenges associated with implementation. Most notably, oxidation by hydroxyl radicals
can produce over 50 different types of modifications, which can complicate MS
analysis.150 Moreover, in its most commonly used forms, a laser or synchrotron source is
necessary to generate the radicals, which adds complexity and limits its wide
applicability.
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Another approach to covalent labeling uses amino acid-specific reagent
molecules to modify solvent exposed residues. A wide range of reagents are available,
ranging from those that have narrow specificity (e.g. succinimides) to those that have
broad reactivity (e.g. DEPC).164 This approach to labeling is simple as it requires no
specialized equipment and typically produces only a single type of product, facilitating
mass spectral analysis. While amino acid-specific reagents have been widely used to
probe monomeric and oligomeric proteins,164 their application to therapeutic proteins
has been very limited. To our knowledge, only the carboxylate-specific reagent pair of 1ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and glycine ethyl
ester (GEE) has been used to probe the structure of a mAb.74 This particular labeling
chemistry is relatively simple to implement; however, because it is limited to only Asp
and Glu residues, it results in relatively poor coverage of the protein’s surface area and
thus low effective structural resolution. Another reagent with broader reactivity such as
DEPC should maintain the simplicity of this type of covalent labeling, while at the same
time increasing resolution. Because DEPC is capable of labeling all nucleophilic residues,
our group has shown that this reagent is capable of monitoring approximately 30% of
surface residues of the average protein.65,176 Such broad reactivity has enabled this
reagent to provide insight into protein structure as well as protein-metal and proteinprotein interactions.54–56,65,164 In this work, we demonstrate the ability of DEPC labeling
to assess structural perturbations in protein therapeutics by investigating three proteins
before and after stressed conditions. We find that covalent labeling is capable of
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identifying stress-induced structural perturbations in protein therapeutics, including the
interface through which the protein therapeutics aggregate.

3.2 Experimental Procedure

3.2.1 Materials

Diethylpyrocarbonate (DEPC), imidazole, iodoacetamide, L-cysteine, papain from
papaya latex, tris(2-carboxyethyl)phosphine (TCEP), and DL-dithiothreitol (DTT) were
obtained from Sigma Aldrich (St. Louis, MO). The mAb immunoglobulin G1 (IgG1) was
purchased from Waters Corporation (Milford, MA). Human β-2-microglobulin (β2m) was
obtained from Fitzgerald Industries International (Concord, MA). Recombinant Human
Growth Hormone (HGH) was purchased from Biovision (San Francisco, CA). Urea was
purchased from Acros Organics (Geel, Belgium). Both immobilized trypsin and
chymotrypsin were obtained from Princeton Separations (Adelphia, NJ). Sodium
phosphate monobasic monohydrate was purchased from EM Science (Darmstadt,
Germany). Sodium phosphate dibasic anhydrous, hydrogen peroxide, methanol, formic
acid, acetonitrile, and water were purchased from Fisher Scientific (Fair Lawn, NJ).
Centricon molecular weight cutoff (MWCO) filters were obtained from Millipore
(Burlington, MA).
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3.2.2 Sample Preparation

β2m and IgG1 were prepared in 50 mM ammonium acetate (pH 7.4) and 50 mM
sodium phosphate buffer (pH 7.4), respectively. Both proteins were then incubated at
75 °C for 15 min (IgG) or 1 day (β2m) for thermal degradation conditions. Oxidative
conditions were carried out by incubating the protein in the presence of 3% H2O2 (w/w)
at room temperature for 1 day. HGH was prepared in 10 mM sodium phosphate buffer
(pH 8.0), and incubated at 65 °C for 2, 12, and 24 hours. After the forced degradation
conditions, the proteins were reacted with DEPC and then analyzed by MS.

3.2.3 DEPC Labeling Reactions

Stock solutions of DEPC were prepared in acetonitrile. The DEPC reactions of
β2m were performed for 1 min at 37 °C and were initiated by adding DEPC in a molar
excess of 2.5. The total reaction volume for the experiments was 100 µL, and the total
amount of acetonitrile added was 1%. Based on our previous work, this low percentage
of acetonitrile has no noticeable influence on protein structure.54–56,65 Experiments with
β2m were performed in triplicate. The reactions were quenched after 1 min by adding
10 mM imidazole. Labeling of IgG1 (5 µM) was performed at a protein to DEPC molar
ratio of 1:4 in a 50 mM phosphate buffer at pH 7.4. The solution was reacted for 5 min
at room temperature before quenching by the addition of imidazole at a 1:50
(DEPC:imidazole) ratio. Five replicate reactions and analyses were conducted on the
IgG1 samples. DEPC labeling of HGH was performed at a 1:5 (protein:DEPC) ratio for 1
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min at room temperature. The amount of acetonitrile added was 1%. The reaction was
quenched by the addition of imidazole at an 80 molar excess to DEPC. Three replicate
reactions and analyses were conducted on the HGH samples.

3.2.4 Proteolytic Digestion

Since β2m and HGH have a single disulfide bond, TCEP (protein:TCEP=1:40 molar
ratio) was added to reduce the disulfide bond and iodoacetamide (100 µM) was added
simultaneously at room temperature for 30 min in the dark to alkylate the reduced Cys
residues. The resulting samples were incubated with 10% (vol/vol) acetonitrile at 50 °C
for 45 min prior to digestion with immobilized chymotrypsin (enzyme/substrate ratio of
1:10) for B2m and immobilized trypsin (1:10) for HGH at 37 °C. After 2 hours, the
reaction mixture was centrifuged for 2 min at 9000 relative centrifugal force (RCF) to
separate the enzyme from the protein. After that, the samples were either immediately
analyzed by LC/MS or flash frozen in liquid nitrogen and stored at -80°C until LC/MS
analysis.
To achieve complete digestion of IgG1, an initial digestion with activated papain
was necessary. To activate papain 0.5 µM of the enzyme was incubated in 1 mM EDTA
and 10 mM L-cysteine at 37 °C for 30 min. Once complete the cysteine concentration
was reduced to less than 2 µM via four spins with a 3000 MWCO filter. The papain
digestion was then performed for 2.5 hours using a 1:100 (papain:IgG1) ratio. IgG1 was
then denatured and its disulfide bonds were reduced in a 50 mM phosphate buffered
solution at pH 7.4 with 1 M urea and 20 mM DTT at 60 °C for 20 min. The reduced
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disulfides were then alkylated with 40 mM iodoacetamide for 2 min. Immobilized
trypsin was then added to achieve a 1:3 (enzyme:substrate) ratio, and the digestion
reaction was allowed to proceed overnight at room temperature. After digestion, the
samples were spun at 9200 RCF for 5 min, and the supernatant was collected, flashfrozen in liquid nitrogen, and stored at -80 °C until analysis via LC/MS.

3.2.5 HPLC Separation

β2m HPLC separations were conducted using an HP1100 HPLC system (Agilent,
Wilmington, DE) with a Discovery C18 column (15 cm × 2.1 mm, 5 μm particle size;
Supelco, St. Louis, MO, USA). Peptide fragments from the proteolytic digests were
eluted using a linear gradient of methanol containing 0.1% acetic acid that increased
from 10% to 100% methanol over 30 min at a flow rate of 0.25 mL/min.
HPLC separations of IgG were performed using a Thermo Scientific Acclaim
PepMap RSLC C18 (15 cm x 50 µm, 2 µm particle size) on an Easy-nLC 1000 system
(Thermo Scientific, Tewksbury, MA). To achieve sufficient separation of the proteolytic
peptides, a shallow gradient was used where %B (0.1% formic acid in acetonitrile) was
increased from 0 to 40% over 90 min. The column was then flushed by jumping to 95 %
B over 15 min. It was then held at 95% B for the remainder of the separation (i.e.
another 20 min). A flow rate of 0.225 µL/min was used.
HPLC analyses of HGH were performed using an Accela LC system (Thermo
Scientific, Tewksbury, MA) with a ZORBAX 300SB-C18 MicroBore RR column (1.0 X 150
mm, 3.5 μm particle size, Agilent, Wilmington, DE). Peptides were eluted over a 5052

minute gradient where %B was increased from 2% to 45% over the first 35 minutes,
then elevated to 80% for an additional 5 minutes. The column was then re-equilibrated
with 0% B for 10 minutes. Blank runs were run in between each sample, and were each
run at a flow rate of 0.05 mL/min.

3.2.6 Mass Spectrometry

On-line high performance liquid chromatography (HPLC) MS analyses were
performed on all protein digests. The HPLC details can be found in the SI. Mass analysis
of β2m proteolytic fragments was carried out on a Bruker AmaZon (Billerica, MA, USA)
quadrupole ion trap mass spectrometer equipped with an electrospray ionization
source. Typically, the electrospray needle voltage was kept at ~4 kV, and the capillary
temperature was set to 250 °C. Either collision-induced dissociation (CID) or electron
transfer dissociation (ETD) was used to obtain tandem mass spectra.
For IgG, MS analyses were performed using a Thermo Scientific Orbitrap Fusion
(Tewksbury, MA) mass spectrometer. The electrospray ionization source was typically
operated at a needle voltage of 2200 volts, and the ion transfer tube temp was set to
300 °C. Tandem mass spectra were collected using CID with a normalized collision
energy of 35%. Due to the large number of measured peaks, an exclusion limit of 60 sec
was activated after five spectra were collected for any given peak. The resolution of the
Orbitrap was set to 60000.
MS analysis for HGH was performed using a Thermo Scientific LTQ-XL Orbitrap
(Tewksbury, MA) mass spectrometer equipped with an electrospray ionization source.
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The ESI needle voltage was kept at 5 kV. Tandem mass spectra were generated using an
HCD collision energy of 35.

3.2.7 Peptide Identification

Raw mass spectral data files were converted to .mgf format using msconvert
software.177 The .mgf files were analyzed with SearchGUI.178 The search engines
X!tandem,179,180 MS Amanda,181 MS-GF+,182 OMSSA,183 and Comet184 were all used.
Spectra were searched against a database constructed from the cRAP database
(http://www.thegpm.org/crap/index.html) with the sequence of the proteins of interest
added. Spectra were searched against the custom database and against the reverse,
decoy database. Variable modification by DEPC of the residues H, Y, K, T, S and the
protein N-terminus was added as a user modification (mass addition of 72.0211).
Variable oxidation of M was also used in searches. Carboxyamidomethylation of
cysteine was used as a fixed modification. Unspecific enzyme cleavage was selected, and
a precursor mass tolerance of 10 ppm was used.
Search data were visualized using Peptideshaker185 with protein, peptide and
PSM FDRs set at 1%. PTMs were scored using the PhosphoRS algorithm. Identification
features were exported in .csv format, and these features were used to construct a
custom database for peak identification in MZmine.
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3.2.8 Peptide Peak Quantification
Raw data files were imported into MZmine,186 and mass detection was done in
centroid mode at the MS1 level. Chromatograms were constructed, deconvoluted and
peak identification was performed with a custom database constructed from the
Peptideshaker export. When multiple files were analyzed, deconvoluted spectra were
aligned using the RANSAC algorithm. The quantified, identified and aligned data were
exported to a .csv file using the export function.

3.2.9 Circular Dichroism

All IgG solutions were diluted to 0.75 µM in 50 mM phosphate buffer at pH 7.4
prior to analysis. For HGH conditions all solutions were diluted to 5 µM in 10 mM
phosphate buffer at pH 8.0. Circular dichroism was measured using a J-715
spectropolarimeter (Jasco, Easton, MD). The scan ranged from 250 to 195 nm with a
scan resolution of 0.5 nm, a scan rate of 100 nm/min, and a response time of 1 sec. Raw
data were converted into mean residue ellipticity using the CD Analysis & Plotting Tool
(CAPITO).187

3.2.10 Fluorescence

The concentration of IgG was diluted to 0.75 µM in 50 mM phosphate buffer at
pH 7.4 prior to analysis. For HGH, the protein was diluted to 5 µM in 10 mM phosphate
buffer at pH 8.0. A Photon Technology International Quantamaster-4SE (PTI, Edison, NJ)
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was used to obtain fluorescence spectra for IgG. Tryptophan fluorescence was collected
using an excitation wavelength of 295 nm and slit widths of 1 nm. Emission scans ranged
from 310-440 nm. A Synergy H1 multi-mode plate reader (BioTek, Winooski, VT) was
used to measure the fluorescence of HGH. Samples were excited at 295 nm and
emissions were monitored from 300-440 nm.

3.2.11 Dynamic Light Scattering

A Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, U.K.) was used to
measure the hydrodynamic radii of native and heat denatured IgG. A 1 mL solution of 1
µM IgG was used for these experiments. Five runs were conducted for each sample, and
volume particle size distribution is reported. For HGH the measurements were carried
out using a Zetasizer Nano-S (Malvern Instruments, Worcestershire, U.K.). HGH was
measured at 5 µM after treatment by the conditions indicated. Measurement duration
was according to preset levels, and intensity/volume distributions of the samples from
at least four runs were recorded in each dataset.

3.2.12 Size Exclusion Chromatography

For SEC experiments, the protein was separated using a SuperSW2000 30 cm ×
4.6 mm column (GE Healthcare Biosciences, Piscataway, NJ) installed on an Agilent
HP1100 series HPLC system (Wilmington, DE). Before injection of the sample, the SEC
column was first equilibrated with a 20 mM ammonium acetate mobile phase (pH = 7.4)
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at a 0.035 mL/min flow rate for 1 h. 20 µL of the protein sample was injected into the
sample loop. A variable wavelength detector set at 214 nm was used for detection.

3.3 Results and Discussion

3.3.1 β-2 microglobulin (β2m)

β2m shares the same β-sandwich fold as each of the domains in IgG and thus
was chosen as an initial model system. The protein under native and both heat- and
oxidatively-degraded conditions was probed using DEPC. Labeling was done at a 2.5:1
molar ratio (DEPC:protein) as previous work from our group had demonstrated that a
labeling ratio of 4:1 or less provided good labeling yield without significantly perturbing
a protein’s structure.65
The modification results for the β2m residues under all three conditions reveal
that β2m undergoes noticeable structural changes upon exposure to elevated
temperature and H2O2 (Table 3-1). The residues that are labeled under native conditions
are displayed as spheres in Figure 3-1A and B. All 16 of these residues are found on the
exterior of the protein and are exposed to solvent, which is consistent with previous
DEPC labeling results for this protein under native conditions.
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Table 3-1. Modification percentages for individual residues of β2m before and after heating at 75 °C for 24
hours or oxidation with 3% H2O2 for 24 hours.
Native
Heated for 1
Β2m
Significant*
3% H2O2
Significant*
day
(control)
N-term

49

±

1

44

±

2

yes

7.6

±

0.3

yes

Lys6

2.5

±

0.1

3

±

0.5

no

0

±

0

yes

Ser11

20

±

3

11.8

±

0.3

yes

6

±

2

yes

His13

32

±

2

17

±

1

yes

4

±

1

yes

Lys19

2.7

±

0.4

2

±

2

no

0

±

0

yes

Ser20

1.1

±

0.3

4.8

±

0.7

yes

1.7

±

0.3

no

Ser28

0.25

±

0.05

0

±

0

yes

0.3

±

0.09

yes

His31

1.9

±

0.2

0.72

±

0.08

yes

0

±

0.1

yes

Ser33

0.68

±

0.09

0

±

0

yes

0.18

±

0.01

yes

Lys41

0.6

±

0.1

1

±

0.1

yes

0

±

0

yes

Lys48

0

±

0

1.2

±

0.2

yes

0

±

0

no

His51

2.2

±

0.3

0

±

0

yes

0.27

±

0.07

yes

Ser55

1.4

±

0.2

0

±

0

yes

0

±

0

yes

Ser57/
Lys58

2.5

±

0.4

0

±

0

yes

0

±

0

yes

Tyr67/
Thr68

2.2

±

0.3

2

±

1

no

6

±

2

yes

Lys91

2.1

±

0.4

2

±

0.2

no

0.1

±

0.2

yes

Lys94

3.1

±

0.6

3

±

0.4

no

0.2

±

0.3

yes

*A difference was considered significant if the p-value, calculated by performing an unpaired T-test, was less than 0.05
(corresponding to a 95% confidence level, n=3)).

After being exposed to thermal stress for 24 hours, the extent and pattern of
labeling significantly changes. The residues highlighted in blue in Figure 3-1A undergo
statistically significant decreases (p-value < 0.05) in labeling extent, while the residues in
red undergo an increase in labeling extent. Because many residues undergo a decrease
in labeling extent and these residues are clustered on one face of the protein, these
results suggest that the protein aggregates upon overnight heating. Support for this
conclusion is found from SEC measurements (Figure 3-2), which reveal protein
aggregates are formed. The residues that decrease in labeling extent (i.e. Ile1, Ser28,
His31, Ser33, Ser55, and Ser57) are likely at the interface(s) of these oligomers.
Moreover, the same region of the protein is buried in the MHC complex that β2m forms
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physiologically.28 This region’s exposure is likely thermodynamically unfavorable in the
monomeric protein, potentially explaining its propensity for aggregation at this site.
Interestingly, two residues (i.e. Lys41 and Lys48) on the loop that connects two of the
aggregating β strands show an increase in labeling after heating, suggesting that this
region of the protein unfolds upon heating to facilitate aggregation.

Figure 3-1 Covalent labeling results for β2m. Spheres represent residues that were labeled with DEPC. The
color indicates whether the residue has undergone any significant change in labeling after being exposed to a
perturbing condition (blue: decrease, red: increase, gray: no change). A) Heating at 75°C for 24 hours. B)
Oxidation with 3% H2O2 for 24 hours. Changes in covalent labeling are mapped onto the NMR structure of
β2m (PDB accession code: 2XKS).

Covalent labeling of the oxidized protein also indicates that the protein
aggregates after exposure to H2O2. Nearly all residues undergo a decrease in labeling
extent (Figure 3-1B), signifying extensive aggregation. Analysis via SEC corroborates this
conclusion (Figure 3-2). While many of the same residues decrease in labeling as in the
heated sample, the additional residues indicate the aggregates are also mediated by
other interfaces. Overall, the covalent labeling experiments with β2m successfully
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demonstrate the ability of this technique to identify structural changes, especially
interfacial sites that are formed upon heat- and oxidatively-induced aggregation.

Figure 3-2 Size exclusion chromatography of β2m before (blue) and after heating (red) and oxidation (black).
Both chromatograms demonstrate the presence of aggregated species. These aggregated complexes are evident
from the peaks eluting earlier than 10.5 min.

3.3.2 Immunoglobulin G (IgG)

The promising results with β2m prompted us to apply the method to IgG under
native and thermally degraded conditions. To minimize structural perturbations to IgG
during the labeling reaction, we limited the DEPC:protein ratio to 4:1. We also
monitored the protein’s structure using CD and fluorescence spectroscopy. Both
techniques demonstrate that the protein undergoes no significant structural
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perturbations after reacting with DEPC at these concentrations (Figure 3-3), confirming
the structural integrity of the protein. We were pleased to find that DEPC labeling of IgG
under these conditions results in the labeling of almost 30% of the amino acids in the
protein (Table S1 and S2 in the SI).

Figure 3-3 Circular dichroism (A) and tryptophan fluorescence (B) of IgG1 under normal (red), heated (Black),
and DEPC-labeled (green) conditions. The essentially identical overlap between the spectra of the normal and
DEPC-labeled samples demonstrates that covalent labeling has little effect on the structure of IgG1.

Upon comparing the labeling results of the thermally degraded sample with
those generated under native conditions, we find that numerous sites undergo changes
in labeling. Figure 3-4 summarizes these results by showing the percent change in DEPC
labeling that each residue undergoes upon heat treatment relative to the unheated
sample. Figure 3-4A illustrates the labeling for IgG’s light chain, while Figure 3-4B shows
the results for the heavy chain.
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Figure 3-4 Bars represent changes in modification of IgG1 after heating from experiments involving five
replicates. Negative values represent residues that are more protected after heating. A) Light chain. B) Top: VH
and CH1 domain of heavy chain. Bottom: CH2 and CH3 domain of heavy chain

Because about 200 residues are labeled in the protein, these results were further
simplified by considering only the statistically significant changes in each domain. The
significant relative changes were broken into bins based on the magnitude of the
change (Table 3-2). Each domain has a relatively equal number of residues undergoing
increases or decreases in labeling; however, almost all of the residues in the light chain’s
variable domain (VL) undergo significant decreases in labeling. This clustering of residues
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suggests that the protein might be aggregating upon heating, and this domain mediates
this aggregation. Indeed, DLS demonstrates that IgG undergoes significant aggregation
after 15 min of heating at 75 ºC (Figure 3-5).
Table 3-2. Number of residues within each domain of IgG1 whose relative labeling change after heating is
statistically significant and whose value falls within the labeled bin.

Domaina

< -80%

< -40%

< -10%

VL

12

8

1

CL
VH
CH1
CH2
CH3

10
13
9
9
5

3
2
2
5
6

3
1
1
0
0

Total
Decrease

>
200%

>
100%

> 10%

Total
Increase

21

4

0

0

4

16
16
12
14
11

12
13
13
4
4

3
1
4
3
1

2
1
2
3
3

17
15
19
10
8

aCL and VL represent the constant and variable domains of the light chain. VH and CH1-3 represent the variable and the
three constant domains of the heavy chain, respectively.

Figure 3-5 Dynamic light scattering data for IgG1 before (top) and after heating at 75 ºC for 15 minutes
(bottom). These data demonstrate that IgG1 aggregates upon heating.
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Greater structural insight is obtained by mapping the data in Table 3-2 onto an
IgG homology model. A homology model was generated by the Swiss-Model
workspace188,189 using an IgG crystal structure (PDB: 1IGY) as a template. As expected,
the VL domain presents a large cluster of residues that undergo a decrease in labeling
(Figure 3-6). Somewhat surprisingly, mapping the labeling data also reveals another
potential interface on the VH domain, which also shows a clustering of residues
undergoing a decrease in labeling. A color coded depiction of the different IgG domains
in a space-filling model can be found in Figure 1-3.
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Figure 3-6 Cartoon representations of IgG1 homology model. Side view (top) and top view (bottom). Spheres
represent residues that are likely at the aggregate interface. Colors represent the magnitude of the reduction
(Purple: >80%, Blue: 40-80%, and Teal: 10-40% reduction in labeling). The likely interfaces on the VL and VH
domains are circled (VL: blue and VH: red).

The possible role that the VL and VH domains play in mediating IgG1 aggregates is
further supported by the aggregation predictor tool Zyggregator (Figure 3-7).190–193
When Zyggregator prediction data are overlaid onto IgG1’s structure (Figure 3-7), there
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are four surface accessible regions in the protein that have a cluster of residues with a
strong propensity to aggregate. Two of the four predicted sites are the VL and VH
domains, which are implicated to be involved in aggregation by covalent labeling (Figure
3-7). The other two predicted regions clearly have smaller surface areas, decreasing
their likelihood of being true interfaces in the aggregates. It is interesting to note that
previous studies are divided on which domains mediate aggregation processes in IgG’s.
Some work suggests that typically the CH2 domain is the primary site of
aggregation,85,194–196 while others suggest the variable regions in the Fab domain as the
sites of aggregation.89,114,197,198 It is quite possible that the aggregation site varies from
antibody to antibody.198 We feel our labeling results provide strong evidence for the role
of the variable regions in the light and heavy chains in mediating aggregation in IgG1.
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Figure 3-7 Propensities for aggregation from Zyggregator as indicated by Z-scores. Z-Score > 2 (red) Z-score >
1 (orange). A higher score denotes an increased likelihood of aggregation. Circled sites highlight the regions
where there is a clustering of residues with a high calculated aggregation propensity. Labeled sites 1 and 2 are
the covalent labeling indicated aggregation sites on the VL domain and the VH domain, respectively.
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3.3.3 Human Growth Hormone

The results from IgG and β2m demonstrate that covalent labeling can identify
proteins which have undergone severe structural perturbations. In order to test the
technique’s ability to identify minor structural changes, we studied HGH. Labeling of this
protein was performed before and after heating at 65 ºC, a temperature that is 12 ºC
below its melting temperature.199 CD and intrinsic fluorescence spectra (Figure 3-8) both
show only minor structural perturbations after heating to this temperature.

Figure 3-8 Circular dichroism (A) and tryptophan fluorescence (B) of HGH under normal (red), heated to 65 ºC
(black), and heated to 75 ºC (green) conditions. Both fluorescence and circular dichroism show only minor
changes in structure after heating. The fluorescence spectrum at 75 ºC is included as a positive control to
demonstrate that fluorescence can reveal structural perturbations for HGH.

Upon DEPC labeling, 41 modification sites are identified (Table S5 in the SI)
corresponding to over 20% of the protein. This amount of labeling ensures sufficient
coverage of the protein’s structure. The labeling percentages of all the labeled sites for
both native and heat-denatured HGH are summarized in Figure 3-9. When comparing
the heat-denatured protein to the natively-structured protein, only six residues are
found to undergo a significant change (p-value < 0.05) in labeling extent. They are His19,
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Thr28, Thr61, Thr136, Lys159, and Tyr165. Of these six, two residues undergo increased
labeling upon heating (Thr136 and Lys159).

Figure 3-9 Covalent labeling results for HGH before and after heating at 65°C for 24 hours. Asterisks (*)
indicate residues that have undergone a statistically significant change. A difference was considered significant if
the p-value, calculated by performing an unpaired T-test, was less than 0.05 (corresponding to a 95% confidence
level at n=3).

To understand the structural implications of these changes, we mapped the six
residues on to a crystal structure of HGH (Figure 3-10, PDB: 1HGU). The two residues
(Thr136 and Lys159) that undergo increased labeling after heating are on opposite ends
of a long disordered region, signifying further melting of this region. The four residues
(His19, Thr28, Thr61, and Tyr165) that undergo decreased labeling are clustered on the
opposite face of the protein.
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Figure 3-10 Summary of the covalent labeling results for HGH. Spheres represent residues that underwent
significant changes in DEPC labeling after heating at 65 ºC for 24 h (blue: decreased, red: increased). Changes
in covalent labeling are mapped onto a crystal structure of HGH (PDB accession code: 1HGU).

While such clustering might suggest aggregation, DLS measurements (Figure
3-11) indicate that the protein does not aggregate under these conditions. Instead, the
DLS measurements reveal that the protein undergoes a slight compaction upon heating.
Therefore, it is possible that the four residues undergo a decrease in labeling extent
because they become less solvent exposed during this compaction process.
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Figure 3-11 Dynamic light scattering data for HGH before (top) and after heating at 65 ºC for 24 h (bottom).
These data demonstrate that HGH undergoes some degree of compaction upon heating.

Under denaturing conditions it has been demonstrated that HGH maintains a
majority of its helical structure. Its loops, however, are known to become significantly
more dynamic than the rest of the protein’s structure.96 Repositioning of these loops
might cause Thr136 and Lys159 to become more solvent exposed, while at the same
time causing His19, Thr28, Thr61, and Tyr165 to become less solvent exposed. Overall,
these data for HGH suggest that DEPC labeling with MS detection is sensitive enough to
detect minor structural perturbations.
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3.4 Conclusions

We have used DEPC-based covalent labeling as a means to monitor the structure
of therapeutic proteins. Through the study of three proteins, β2m, IgG, and HGH, we
have shown that DEPC labeling is capable of identifying specific structural perturbations
that occur upon exposing these proteins to common forced-degradation conditions.
Because the label can probe up to 30% of the residues in a protein, this method
provides a high degree of structural resolution relative to other covalent labeling
reagents. DEPC labeling is particularly valuable for identifying interfacial residues in
protein aggregates. For example, this technique was able to identify the variable
domains of the light and heavy chain as the regions that mediate aggregation of IgG1
upon heating. DEPC labeling is also able to distinguish relatively minor perturbations in
protein structure as illustrated by the experiments with HGH. Given the high effective
resolution provided by DEPC labeling and the ease with which it can be performed
relative to other MS-based techniques, we predict that this approach will be a powerful
tool for studying therapeutic proteins.
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CHAPTER 4
LABEL SCRAMBLING DURING CID OF COVALENTLY LABELED PEPTIDE IONS

This chapter is adapted from a paper published as: Borotto, N. B., Degraan-Weber, N.,
Zhou, Y., and Vachet, R. W. (2014) Label Scrambling During CID of Covalently Labeled
Peptide Ions. J. Am. Soc. Mass Spectrom. 25, 1739-46.
4.1 Introduction

Covalent labeling along with mass spectrometry is being increasingly used to
study higher order protein structure and protein-protein complexes.148–151,164,200–203
Covalent labels that are typically used either label specific amino acid residues (e.g.
succinimides for lysines) or a range of amino acid residues (e.g. hydroxyl radicals). We
have recently shown that diethylpyrocarbonate (DEPC) is a promising reagent molecule
because of its ability to modify a wide range of amino acids.55,56,65,164,165 This potential to
modify numerous amino acids enables DEPC to probe approximately 30% of the average
protein.165 Usually, proteins that are labeled with DEPC are then subjected to proteolysis
so that the modification sites can be pinpointed to individual residues, thereby
improving the resolution of this method.
While DEPC has been successfully used to study the structures of proteins and
protein complexes, this labeling reagent introduces an electrophilic site into the side
chains of the residues it modifies, opening up the possibility for some unwanted
chemistry. For example, we recently demonstrated that, in solution, cysteine residues
have the ability to capture carbethoxy groups from other residues that were modified
by DEPC. This unwanted label transfer can be eliminated by deactivating cysteine’s
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strong nucleophilic character via alkylation just after DEPC labeling of the protein is
finished.176 The presence of a new electrophilic site might also affect the gas-phase
chemistry of DEPC-labeled peptides especially when subjected to slow collisional
activation in a quadrupole ion trap mass spectrometer. Indeed, Reid and co-workers and
others have reported that phosphorylated peptide ions can have their phosphate group
transferred from one amino acid to another upon CID.204–206 The result is the incorrect
assignment of the phosphorylation site on the peptide. In addition to the scrambling of
phosphate groups in peptide ions, methyl,207 acetyl, and formyl groups208 have also been
documented to undergo transfer from one amino acid to another during CID in the gas
phase.
With the known chemistry of DEPC and these previous studies in mind, we set
out to investigate whether DEPC label scrambling can occur during CID of DEPC labeled
peptide ions. Through the study of numerous peptides, we find that label transfer can
occur in DEPC-labeled peptides, and it occurs with similar characteristics to phosphate
group transfer in phosphorylated peptides.

4.2 Experimental Methods

4.2.1 Materials

Diethylpyrocarbonate (DEPC), imidazole, iodoacetamide, and tris(2carboxyethyl)phosphine (TCEP) were obtained from Sigma Aldrich (St. Louis, MO).
Angiotensin 1-10 (DRVYIHPFHL) , angiotensin 1-13 (DRVYIHPFHLVIH), apelin 13
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(QRPRLSHKGPMPA), β amyloid (YEVHHQKLVFF), semastatin
(SPWTKCSATCGGGHYMRTR), neuromedin-C (GNHWAVGHLM ) and adrenocorticotropic
hormone (ACTH) 1-13 (SYSMEHFRWGKPV) were obtained from the American Peptide
Company (Sunnyvale, CA). Human β-2-microglobulin (β2m) was obtained from Lee
Biosolutions (St. Louis, MO). Immobilized chymotrypsin and triethylamine acetate (pH
8.0) were obtained from Princeton Separations (Adelphia, NJ). Ammonium acetate,
methanol, formic acid, acetonitrile, and water were purchased from Fisher Scientific
(Fair lawn, NJ). Centricon molecular weight cutoff (MWCO) filters were obtained from
Millipore (Burlington, MA).

4.2.2 DEPC Labeling Reactions

Peptide solutions with a concentration of 100 µM in 10 mM ammonium acetate
were reacted with DEPC at either a 1:1 or 1:4 (peptide:DEPC) ratio for 2-5 min at 37°C. A
6 mM stock solution of DEPC in acetonitrile was added to obtain the final DEPC
concentration. The final DEPC concentration resulted in a total acetonitrile
concentration that was less than 2% (v/v) of the reaction mixture. The reaction time and
ratio were chosen to ensure that the unmodified and the singly modified peaks were the
most prominent products. The protein β2m was reacted with DEPC at a 1:4
(protein:DEPC) ratio for 1 min at 37°C. In all cases, the DEPC reactions were quenched
by the addition of 10 mM imidazole.65
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4.2.3 Proteolytic Digestion

Prior to proteolytic digestion of β2m, the quenching agent, imidazole, was
removed using a 10,000 MWCO filter, resulting in a 40 µL solution of 250 µM β2m. β2m
was then incubated in a buffer solution (100 mM triethylamine at pH 8.0) with 10% (v/v)
acetonitrile at 50 °C for 45 min. Next β2m was reacted with TCEP (1:40 ratio) and
iodoacetamide (1:80 ratio) in the dark for 30 min to reduce its disulfide bond and
alkylate the resulting free thiols. Immobilized chymotrypsin was then added to achieve a
1:10 ratio of enzyme to substrate. The digestion reaction was allowed to proceed at 37
°C for 2 hours.

4.2.4 HPLC Separation

HPLC separations were performed using a Supelco Discovery C18 column (15 cm
x 2.1 mm, 5 µm particle size, St. Louis, MO) on an HP1100 HPLC system (Agilent,
Wilmington, DE). To achieve sufficient separation of DEPC-labeled peptide isomers, an
isocratic elution was used (40% acetonitrile in water with 0.1% formic acid) for 20 min.
This was followed by a 0.5%/min increase of acetonitrile for an additional 20 min. A flow
rate of 0.35 mL/min was used, and the effluent from the column was split by four prior
to introduction into the mass spectrometer. The proteolytic digests were eluted using a
linear gradient of methanol ranging from 10 – 100% methanol over 30 min. This mobile
phase contained 0.1% acetic acid and had a flow rate of 0.25 mL/min.
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4.2.5 Mass Spectrometry

Mass analysis was performed using either a Bruker Esquire-LC or a Bruker
AmaZon (Billerica,MA) quadrupole ion trap mass spectrometer. These instruments are
equipped with electrospray ionization sources, and the needle voltage was typically set
to 3000 V. The capillary temperature was set to 300°C. Both CID and ETD were used to
obtain tandem mass spectra. The ion isolation width for both methods was set to 1.0
Da. CID voltages were typically between 0.65 and 1.1 V and were chosen to achieve
optimal dissociation efficiency. For ETD experiments, the low m/z cutoff was typically
set to 135, and the reaction time was typically set to 150 ms.

4.3 Results and Discussion

4.3.1 CID for the Label Site Identification

CID is commonly used to determine label locations in covalently labeled peptides
and is typically successful. As an example, CID of the peptide apelin 13
(QRPRLSHKGPMPA) can readily enable the identification of the DEPC-labeled residues
upon a 2 minute reaction with this reagent (Figure 4-1). LC/MS analysis of the labeled
peptide suggests that there are three labeled sites as indicated by the chromatogram in
Figure 4-1a. By examining the sequence ions upon CID of each peak in the
chromatogram, the specific amino acid residues labeled by DEPC can be assigned. For
DEPC-labeled apelin 13, the CID spectrum of the second chromatographic peak shows a
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series of b ions that are all labeled, and several y ions that are not labeled, indicating
that the N-terminus is the labeled site (Figure 4-1b). The CID spectrum of the third
chromatographic peak is consistent with a label on Lys8, as suggested by labeled y6, y7,
y9, and y11 product ions, unlabeled y4 and y5 ions, labeled b8 and b11 ions, and unlabeled
b2 and b7 ions (Figure 4-1c). The final chromatographic peak corresponds to a labeled
His7 product. This assignment is evident from the labeled y7, y9, and y11 product ions,
unlabeled y4, y5, and y6 ions, labeled b7, b8 and b11 ions, and an unlabeled b2 ion (Figure
4-1d).
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Figure 4-1 (a) Total ion chromatogram after HPLC separation of DEPC-labeled apelin 13. (b) CID spectrum of
the (M+2H)2+ ion of the second chromatographic peak from the DEPC-labeled sample of apelin 13, indicating
that the N-terminus is modified. (c) CID spectrum of the (M+2H)2+ ion of the third chromatographic peak from
the DEPC-labeled sample of apelin 13, indicating that Lys8 is modified. *Interfering ions make assignment of
the labeled and unlabeled versions of the y6 ion somewhat ambiguous. (d) CID spectrum of the (M+2H)2+ ion of
the fourth chromatographic peak from the DEPC-labeled sample of apelin 13, indicating that His7 is modified.
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4.3.2 Ambiguous Label Assignment by CID

While CID often provides correct labeling site information, as exemplified by the
data for apelin 13, we have also found evidence that covalent labels can be scrambled
from one site to another during the CID process. The CID data of DEPC labeledangiotensin I illustrates this phenomenon. Upon labeling this peptide with DEPC for 5
min, on average a single modification site per peptide is measured, resulting in four
isomers as indicated by the chromatogram in Figure 4-2a. Each peak in the
chromatogram corresponds to a chemically distinct structure, and indeed the CID data
for the first (Figure 4-2b) and second (Figure S1 in the Supplemental Information)
labeled peaks are consistent with this assertion, as Tyr4 and the N-terminus,
respectively, are identified as the modified sites.
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Figure 4-2 (a) Total ion chromatogram after HPLC separation of DEPC-labeled angiotensin. (b) Example CID
spectrum of the (M+2H)2+ ion of the second chromatographic peak from the DEPC-labeled sample of
angiotensin I, indicating that Tyr4 is modified. Unlabeled y2 to y6 ions, labeled y7 to y9 ions, labeled b5 to b9 ions,
and an unlabeled b2 ion indicate that Tyr4 is labeled. (c) CID spectrum of the (M+2H)2+ ion of the final
chromatographic peak from the DEPC-labeled sample of angiotensin I. The presence of both labeled and
unlabeled b6, b8, y4, and y2 product ions causes the labeled site to be ambiguous. (d) ETD spectrum of the
(M+3H)3+ ion of the final chromatographic peak from the DEPC-labeled sample of angiotensin I, indicating that
His6 is labeled.
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The identity of the labeled sites for the modified peptides associated with the
final two chromatographic peaks, however, are not as clear. This fact is most evident
from the presence of both labeled and unlabeled versions of the b6, b8, y4, and y2
product ions in both spectra (Figure 4-2c and S2). One possible explanation for this is
that these chromatographic peaks correspond to two unseparated isomers – one
modified at His6 and the other at His9. This possibility is unlikely considering the great
care taken to identify LC conditions to separate any isomers present. Moreover, the ETD
spectra of these peaks (Figure 4-2d and S3) indicate that only His6 is modified with no
evidence for the modification of His9. This conclusion comes from the series of c and z
product ions in which ions that include His6 are labeled and all that do not are
unlabeled. Incidentally, the ETD spectra of peaks 1 and 2 lead to the same conclusions
about modification sites as the CID data (see Figures S4 and S5). Another possible
explanation is that the DEPC label is lost as a neutral. This would, for example, explain
the presence of both labeled and unlabeled b6 and b8 product ions in the CID spectrum;
however, the absence of an unlabeled b9 ion and no evidence for label loss during the
CID of other DEPC-labeled peptides (e.g. apelin 13 in Figure 4-1) suggests that label loss
is not the cause. Moreover, label loss cannot explain the presence of labeled y2 and y4
ions. These latter ions can only arise from the label being transferred to His9.
Upon considering the data for DEPC-labeled angiotensin I, we propose that the
CID data for the final two chromatographic peaks of modified angiotensin I arise via a
collision-induced transfer of the DEPC label from one His residue to another. Such a gas82

phase rearrangement of a side chain modification has been seen before204–208 during CID
analyses, as indicated in the introduction. The migration of the DEPC label from His6 to
His9 during collisional activation of angiotensin I can explain the existence of all
observed ions and is consistent with differences in dissociation mechanisms between
ETD and CID. Unlike label loss, transfer of DEPC from His6 to His9 explains, for example,
why the b9 product ion is only observed as a labeled species. The fact that label
migration does not take place during ETD makes sense due to the non-ergodic nature of
its dissociation mechanism. We suspect that the scrambling of the label is driven by the
fact that addition of DEPC to a histidine side chain results in an electrophilic site that is
vulnerable to attack by other nucleophilic sites on the peptide. In the case of
angiotensin, this nucleophilic site could be the other, unlabeled histidine residue. A
possible mechanism is illustrated in Figure 4-3.

Figure 4-3 Possible mechanism of rearrangement, where the DEPC label on one histidine side chain is
transferred to another via a nucleophilic attack.

Another peptide that appears to undergo label scrambling during CID is the
peptide adrenocorticotropic hormone (ACTH). LC/MS analysis of DEPC labeled ACTH
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indicates that two amino acids are labeled in this peptide (Figure 4-4a). In this case, the
label sites associated with both chromatographic peaks from the labeled peptide are
ambiguous when CID is used. The tandem mass spectrum of the first labeled peak
suggests scrambling between the N-terminus, His6, and Lys11 (Figure S6) as indicated by
the presence of labeled and unlabeled versions of the b2 - b10 series of product ions and
the y6 - y11 series of product ions. The fact that the labeling site is clearly identified as
the N-terminus when dissociated by ETD (Figure S7) suggests that unseparated isomers
are not the source of this ambiguity. CID of the second labeled chromatographic peak
suggests both His6 and Lys11 as the labeled sites based on the existence of labeled and
unlabeled versions of the b6 - b10 series of product ions and y3 - y7 series of product ions
(Figure 4-4b). In contrast, the ETD spectrum of this labeled peptide readily identifies
His6 as the labeled site (Figure 4-4c).
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Figure 4-4 (a) Total ion chromatogram after HPLC separation of DEPC-labeled ACTH. (b) CID spectrum of the
(M+2H)2+ ion of the first labeled chromatographic peak from the DEPC-labeled sample of ACTH. The presence
of both labeled and unlabeled b10, b9, b8, and y7 product ions suggests label scrambling. (c) ETD spectrum of
the (M+3H)3+ ion of the second labeled chromatographic peak from the DEPC-labeled sample of ACTH,
indicating that His6 is labeled.

4.3.3 Effect of Charge State on Labeling Scrambling

Previous work has shown that the gas-phase rearrangement of phosphate and
methyl groups in peptide ions is dependent on the precursor ion’s charge state and the
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subsequent proton mobility within the ion.204,207 Phosphorylated and methylated
peptide ions with non-mobile and partially mobile protons were found to have a higher
propensity to rearrange. Proton mobility in this context refers to the number of net
protons on the peptide ion as compared to the number of basic residues in the peptide.
Non-mobile protons are present when the number of net protons is lower than the
number of basic residues in the peptide. To test whether proton mobility influences
DEPC label scrambling, we compared the CID spectra of the [M+2H+DEPC]2+ and
[M+3H+DEPC]3+ ions of the fifth chromatographic peak of labeled angiotensin (i.e. peaks
in Figure 4-2a). Interestingly, the different charge states result in drastically different
dissociation patterns with regard to label scrambling. There are no longer any labeled y2
or y4 product ions observed upon dissociation of the +3 charge state (Figure 4-5a); these
ions were key indicators of label scrambling for the +2 ion (see Figure 2c). In addition,
the unlabeled b6 and b8 ions, which also implied label scrambling in the +2 ion, are
substantially reduced in relative abundance.
A similar influence of proton mobility on label scrambling is also observed for
ACTH. As shown earlier in Figure 4-4b, the +2 charge state of third chromatographic
peak exhibits scrambling upon activation with CID. When the +3 charge state of this
same labeled peptide is dissociated using CID, no evidence for scrambling is observed
(Figure 4-5b). The absence of unlabeled b6, labeled y3, and y7 product ions in this
spectrum removes all ambiguity about the label assignment. The dramatic influence of
charge state on the dissociation behavior of these DEPC-modified peptides further
supports the notion that label scrambling is occurring.
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Figure 4-5 (a) CID spectrum of the (M+3H)3+ ion of the final labeled chromatographic peak from the DEPClabeled sample of angiotensin I. The absence of labeled y2 and y4 product ions indicates label scrambling is not
occurring. (b) CID spectrum of the (M+3H)3+ ion of the second labeled chromatographic peak from the DEPClabeled sample of ACTH. The absence of unlabeled b6, labeled y3, and y7 product ions in this spectrum indicates
label scrambling is not occurring.

4.3.4 Prevalence of Label Scrambling

To test the pervasiveness of label scrambling, we examined several other labeled
peptides, including ones from a proteolytic digest of the protein β-2-microglobulin that
had been labeled with DEPC for 1 minute. Each collection of peptides was separated by
LC and then subjected to both CID and ETD. In all, 34 different labeled sites were probed
(Table 4-1). The criteria for concluding that label scrambling had occurred were: (i)
unlabeled and labeled versions of product ions were observed during CID and (ii) CID
and ETD identified different labeled sites in a given peptide. Of these 34 labeled
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peptides, nine showed evidence for scrambling. Interestingly, all nine had a histidine
residue as either the originally labeled site or the site to which the labeled was
transferred, indicating the lability of labeled histidine residues. Another interesting
observation from this limited data set is that an acidic residue is present in all the
peptides that undergo scrambling. Because of the effect of proton mobility on the
prevalence of this scrambling reaction (see Figure 4-5), it is possible that intramolecular
interactions between charged groups may be necessary to facilitate this reaction.
Further work is clearly needed, though, to more fully understand how amino acid
sequence affects this scrambling reaction.
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Table 4-1 DEPC-labeled sites on peptides as identified by ETD and CID and whether scrambling has occurred.
Sequence
ETD of
CID of
Scrambling in
CID of
Scrambling in
(M+3H)3+
(M+3H)3+
(M+3H)3+?
(M+2H)2+
(M+2H)2+?
DRVYIHPFHL peak 1
Y4
Y4
No
Y4
No
DRVYIHPFHL peak 2
N-term
N-term
No
N-Term
No
DRVYIHPFHL peak 3
H6
H6
No
H6, H9
Yes
DRVYIHPFHL peak 4
H6
H6
No
H6, H9
Yes
GNHWAVGHLM-NH2 peak 1
N-Term
N-Term
No
N-Term
No
GNHWAVGHLM-NH2 peak 2
H8
H8
No
H8
No
GNHWAVGHLM-NH2 peak 3
H3
H3
No
H3
No
GNHWAVGHLM-NH2 peak 4
H8
H8
No
H8
No
GNHWAVGHLM-NH2 peak 5
H3
H3
No
H3
No
DRVYIHPFHLVIH peak 1
Y4
No
Y4
No
DRVYIHPFHLVIH peak 2
N-term
No
N-term
No
DRVYIHPFHLVIH peak 3
H9
No
H6, H9, H13
Yes
DRVYIHPFHLVIH peak 4
DRVYIHPFHLVIH peak 5
DRVYIHPFHLVIH peak 6
SYSMEHFRWGKPV peak 1

H9
H13
H6
N-term

N-term

No
No
No
No

H6, H9
H9, H13
H6, H9
N-term, H6, K11

Yes
Yes
Yes
Yes

SYSMEHFRWGKPV peak 2
H6
H6
No
H6, K11
Yes
YEVHHQKLVFF peak 1
H4
H4, H5
Yes
H4, H5
Yes
YEVHHQKLVFF peak 2
N-term
N-Term
No
N-term
No
YEVHHQKLVFF peak 3
H4
H4
No
H4
No
YEVHHQKLVFF peak 4
H5
H5
No
H5
No
YEVHHQKLVFF peak 5
K7
K7
No
K7
No
SPWTKCSATCGGGHYMRTR
Y15
No
Y15/H14*
No
peak 1
SPWTKCSATCGGGHYMRTR
H14
No
H14
No
peak 2
SPWTKCSATCGGGHYMRTR Y15/H14*
No
Y15/H14*
No
peak 3
SPWTKCSATCGGGHYMRTR
N-term
No
N-Term
No
peak 4
SPWTKCSATCGGGHYMRTR
K5
No
K5
No
peak 5
SRHPAENGKSNF
S1/R2
No
N-term
No
SRHPAENGKSNF
H3
No
H3
No
IQRTPKIQVY
K6
No
Y3
No
IQRTPKIQVY
N-term
No
N-term
No
KNGERIEKVEHSDL
K1
No
K1
No
SQPKIVKW
K4
No
K4
No
Glp-HWSHGWYPG-NH2
N-term
N-term
No
N-term
No
peak1
Glp-HWSHGWYPG-NH2
His5
His5
No
His5
No
peak2
Glp-HWSHGWYPG-NH2
His2
His2
No
His2
No
peak3
Glp-HWSHGWYPG-NH2
His5
His5
No
His5
No
peak4
SRHPAENGKSNFLNCY
C15
No
C15
No
* Tandem mass spectrometry is unable to identify which of the listed residues is labeled due to the absence of the
appropriate product ions.
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4.4 Conclusions

Covalent labeling is increasingly used to study the surface structure of proteins
and protein complexes, and DEPC is a labeling reagent that has shown great promise in
these experiments because of its ability to label multiple residues simultaneously.
Identifying the labeled sites is often done using CID after proteolytic digestion of the
protein, but in this work, we show that scrambling of the DEPC label to another site on a
peptide can occasionally occur during CID, resulting in ambiguous labeling site
assignments. Like previous studies that reported the scrambling of functional groups
(e.g. phosphate groups) on modified peptides, this scrambling occurs most readily under
low proton mobility conditions. Also, scrambling does not appear to occur when ETD is
used to dissociate the labeled peptides; this is consistent with the known mechanistic
differences between CID and ETD. Based on the analysis of over 30 labeled peptides, we
find evidence for scrambling about 25% of the time. In all the cases where scrambling is
observed, histidine residues are involved. The increased tendency of histidine residues
to undergo scrambling has important consequences as this residue is the most reactive
amino acid with DEPC. A solution to this problem may be to produce larger peptides
upon proteolysis so that the labeled peptides have higher charge states and are thus
more amenable to ETD. Alternatively, supercharging agents could be used to produce
higher peptide charge states to avoid the low proton mobility conditions that foster
label scrambling during CID.
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS

5.1 Summary

This dissertation has investigated the application of MS-based techniques as a
means to study protein structure. These techniques involve the use of chemical
modifications to label solvent exposed sites. These modified sites are then measured via
mass spectrometry. The location and frequency of these modifications are indicative of
solvent accessibility or, in some cases, the dynamics. These values and, more
importantly, changes in these values give insight into the tertiary structure and changes
in tertiary structure near each label. These MS-based techniques have proven to be a
powerful tool.
These methods were first applied to the amyloid forming protein β2m. This work
illustrates that the binding of Cu(II) alone is capable of inducing the transformation of
β2m into an amyloid competent state. Thus, explaining its unique ability to induce
amyloid competent aggregation. In order to perform this, NMR and crystallographic
structures of amyloidogenic conformers induced by other conditions were investigated
in order to find common structural attributes. Two probable structural changes were
found: (1) the burial of Trp60 and (2) the fraying of the B-, D-, and E- strands. All three
complexes were probed looking for these changes. As expected, Cu(II) binding induces
both of these changes. Ni(II) and Zn(II) however, did not. Suggesting that indeed, Cu(II) is
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the only metal that induces the conformational change into the amyloidogenic
conformer.
This research also potentially explained the amorphous aggregation of β2m upon
the binding of Zn(II). This binding was shown to increase the dynamics of β2m in
multiple strands of the protein. This increase in dynamics may be indicative of structural
instability, which could then lead to aggregation. This is supported by the fact that Zn(II)
binding has been shown to destabilize the structure of β2m by as much as 14 kJ/mol.44
Two other conclusions that can be drawn from the work is that metal binding proximal
to Pro32 and His31 alone is not sufficient to induce the conversion into the
amyloidogenic conformer and that the destabilization of the D-strand alone is not
enough to induce aggregation.
We then investigated the ability of a DEPC-based covalent labeling technique as
a means to monitor the structure of therapeutic proteins. This was accomplished
through the study of three proteins, β2m, IgG, and HGH. This work demonstrated that
DEPC was able to identify structural perturbations after exposure to degradation
conditions. These amino acid specific techniques require the simplest analysis and in the
case of DEPC can probe up to 30% of the residues in a given protein, thus, providing a
high degree of structural resolution when compared to other residue specific covalent
labeling reagents. DEPC labeling is particularly valuable for identifying the interfaces of
protein aggregates. In the case of IgG for example, the interface of heat induced
aggregates was shown to be on the variable domains of the light and heavy chain. DEPC
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labeling is also able to distinguish relatively minor perturbations in protein structure as
illustrated by the experiments with HGH.
In order to identify the location of these covalent labels in the experiments
above, the protein is subjected to proteolysis by trypsin. The resulting proteolytic
fragments are then subjected to collision induced dissociation and the resulting tandem
mass spectra can be used to identify the label. In this work however, we show that
these DEPC labels can scramble to another site on a peptide during CID, resulting in
ambiguous labeling site assignments. Similarly to the scrambling of other functional
groups (e.g. phosphate groups) on modified peptides, this scrambling occurs most
readily under low proton mobility conditions. This scrambling does not appear to occur
when ETD is used to dissociate the labeled peptides; this is consistent with the known
mechanistic differences between CID and ETD. Based on the analysis of over 30 labeled
peptides, we find evidence for scrambling about 25% of the time. In all the cases where
scrambling is observed, histidine residues are involved. The increased tendency of
histidine residues to undergo scrambling has important consequences as this residue is
the most reactive amino acid with DEPC. A solution to this problem may be to produce
larger peptides upon proteolysis so that the labeled peptides have higher charge states
and are thus more amenable to ETD. Alternatively, supercharging agents could be used
to produce higher peptide charge states to avoid the low proton mobility conditions
that foster label scrambling during CID.
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5.2 Future directions

The following sections will discuss the potential applications, characterizations,
and improvements for MS-spectrometry based structural techniques. This will also
further discuss the mechanisms of DEPC scrambling and β2m aggregation.

5.2.1 The applications of Trp60 labeling

The ability to easily monitor the conversion of β2m into the amyloidogenic
conformer is a powerful tool. It could be utilized to probe all known conditions shown to
induce β2m oligomerization. Cataloging which conditions promote a mechanism similar
to that of Cu(II) binding could shed light on the amyloidosis of proteins as a whole.
There are several small molecules (i.e. Epigallocatechin-3-gallate and suramin)
that have been shown to inhibit or modulate the formation of fibrils. The mechanisms
by which these drugs perform this modulation are unknown. This labeling technique
could be used to identify if these molecules act on the amyloidogenic conformer or
prevent its formation.
Previous work has shown that ΔN6 is capable of transforming natively folded
β2m into amyloids. HNSB labeling could potentially be a way to monitor this
transformation and potentially measuring its kinetics. As of now, to our knowledge, no
other method capable of probing the kinetics of this reaction has been developed.
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5.2.2 Investigating the sensitivity of DEPC labeling

Protein therapeutics are rapidly transforming the pharmaceutical industry.
Current technologies are challenged to provide the rapid, high resolution analyses of
protein higher order structures needed to ensure drug efficacy and safety. In order for
DEPC labeling to become widely applicable in this field it must be sufficiently
characterized against currently used methodology. Its ability to measure subtle
structural changes upon mishandling is of particular interest.

5.2.3 Mechanism of Scrambling

Covalent labeling along with mass spectrometry is finding more use as a means of
studying the higher order structure of proteins and protein complexes.
Diethylpyrocarbonate (DEPC) is an increasingly used reagent for these labeling
experiments because it is capable of modifying multiple residues at the same time. As
this technique grows in use it is important to understand the mechanism behind this
scrambling. Thus, investigating the effect of distance and chemistry on this scrambling is
vital. Additionally, investigating the influence of acids or lack thereof on this scrambling
could also be enlightening.
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